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The 28% of female patients with cancer disease in Italy is affected by mammary 
carcinoma. Moreover, breast cancer is the first most frequent cause of cancer death 
among Italian women. About 15-20% of human mammary carcinomas overexpress the 
proto-oncogene HER2, a tyrosine kinase receptor that belongs to EGFR family. HER2-
positive tumors are more aggressive, and the prognosis of the patients is worse. 
HER2 is known to be involved in tumor angiogenesis, through the increase of the 
expression of VEGF, COX-2 and HIF-α. In patients, the simultaneous expression of 
HER2 and VEGF correlates with a poorer prognosis. HER2 has also been linked to 
vasculogenic mimicry, that is the formation of perfused blood vessels by tumor cells.  
Despite the correlation between HER2 expression and tumor angiogenesis, anti-
angiogenesis drugs, such as bevacizumab, sunitinib and pazopanib, failed to reach 
sufficient efficacy in patients to be approved for HER2-positive breast cancer. 
About half of HER2-positive breast cancer presents an alternative splicing 
isoform called Δ16 because of the lack of exon 16. The absence of 48 amino acids in the 
juxtamembrane region changes the conformational structure of the receptor, causing 
the formation of more stable homodimers. This greater capability of homodimerization 
confers higher signaling activity that leads to higher invasivity in vitro and higher 
tumorigenicity in vivo. Moreover, the presence of Δ16 has been linked to reduced 
sensitivity to trastuzumab in vitro, but not in vivo. 
In Δ16-transgenic mice (Δ16-HER2 mice), the spontaneous development of 
mammary tumors occurs much earlier than in HER2-transgenic mice (FVBhuHER2 
mice). A double-transgenic mouse model that bear both isoforms of HER2 (F1 mice) 
was recently developed, in which the spontaneous carcinogenesis occurs as early as in 
Δ16-HER2 model. 
The three above-mentioned mouse models have been studied at the Laboratory 
of Immunology and Biology of Metastases directed by Prof. Pier-Luigi Lollini 
(Department of Experimental, Diagnostic and Specialty Medicine, University of 
Bologna, Italy), where this project has been carried out. In the tumors developed on 
these models, angiogenesis seems to occur in different ways. In FVBhuHER2 mice, 
tumors display a reddish and hemorrhagic aspect with a soft texture. Δ16-HER2 
tumors, on the other hand, are often pale and solid. In F1 tumors, both characteristics 
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can be present. In this way, HER2 and Δ16 seem to drive different angiogenic 
phenotypes. 
Therefore, the aim of this thesis was to better analyze the role of the two isoforms 
in determining different patterns of vascularization, especially in the light of the fact 
that the role of the splice isoform Δ16 in angiogenesis has never been investigated so 
far. The different vascularization has been put in relation to the different effects of anti-
angiogenic and anti-HER2 drugs. This study has been performed through histological, 
functional and molecular analysis of the tumors of FVBhuHER2, Δ16-HER2 and F1 
female mice, in relation to the expression of the full-length HER2 and Δ16. 
Furthermore, cell lines derived from these tumors have been used to study 
angiogenesis in vitro. 
The analysis of the vascularization in F1 tumors, in which one isoform or both 
can be expressed, revealed that the presence of full-length HER2 is crucial for the 
establishment of the FVBhuHER2-like phenotype, that is with few large vessels. When 
only Δ16 is expressed, the vascular pattern with numerous small vessels, that is typical 
of Δ16-HER2 tumors, is present. 
The dominant role of full-length HER2 in tumor angiogenesis has been 
confirmed in a dynamic in vivo model of modulation of the expression of this isoform. 
In two Mouse-Derived Isograft (MDI) models, fluctuations of the levels of expression 
of HER2 determined the acquisition of different vascular patterns: when the levels of 
HER2 rose, the vessels decreased in number and were larger, and when the levels of 
HER2 decreased, the vessels became more and smaller. 
The differences between the vascular patterns sustained by the two isoforms not 
only involved phenotypic aspects, but they also differed from the functional, molecular 
and therapeutic point of view. In particular, the vasculature with few large vessels 
typical of HER2-expressing tumors was less permeable to drugs, as it has been proved 
by the evaluation of the accumulation of doxorubicin and trastuzumab by flow 
cytometry. Moreover, FVBhuHER2 tumors were less sensitive to anti-angiogenic drugs 
such as sunitinib and pazopanib than Δ16-HER2 tumors. Sunitinib and pazopanib had 
an effect on Δ16-HER2 tumors both through an anti-angiogenic mechanism by 
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reducing the number of vessels inside treated tumors, and through an anti-tumoral 
effect by blocking cell proliferation, as proved by in vitro studies. 
A molecular profile with a higher number of genes related to sprouting 
angiogenesis was found in FVBhuHER2 tumors, suggesting that this process might be 
more actively induced and likely less coordinated than in Δ16-HER2 tumors.  
A less regular angiogenesis may explain these characteristics in FVBhuHER2 
tumors. A higher presence of CD44+ CD24-/low cells has been found in a FVBhuHER2-
derived cell line. Studies reported in literature have linked the presence of stem cell 
populations within tumors with vasculogenic mimicry. Vasculogenic mimicry has been 
also associated with the capability of forming tubes on Matrigel. This ability was found 
higher in HER2-expressing cell lines, while Δ16-expressing ones were not able to form 
any tube. The tube formation ability was affected by sunitinib in vitro through the 
decrease of tube formation activity. 
Sunitinib was also effective on triple-negative breast cancer, both in vitro and in 
vivo. 
In conclusion, HER2 isoforms have been found to have a crucial role in tumor 
angiogenesis. The dominant behavior of full-length HER2 affects the regularity of the 
vascular pattern, determining a vasculature that is less permeable to drugs and 
therefore less sensitive to anti-angiogenic and targeted agents. A molecular profile with 
more genes involved in sprouting angiogenesis suggests the need to further study the 
role of full-length HER2 in tumor vascularization, to find new targets to improve the 
pharmacological response to therapies. 
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1. Angiogenesis 
The structure of complex organisms such as vertebrates requires an adequate supply of 
oxygen and nutrients to tissues. This supply is guaranteed by an extended network of 
blood vessels throughout the entire body (Adair and Montani, 2010). 
The mechanisms by which blood vessels can be created are multiple. During 
early embryonic development, de novo blood vessels form by a process called 
vasculogenesis that consists in the formation of endothelium from mesoderm cell 
precursors, called angioblasts (Risau and Flamme, 1995). Vasculogenesis does not take 
place after birth in physiological conditions. On the contrary, angiogenesis (from the 
Greek word Angêion, meaning vessel) consists in the growth of vessels from pre-
existing vasculature and can occur both in uterus and after birth (Adair and Montani, 
2010). Angiogenesis can also occur in pathological conditions such as cancer, but the 
vessels that form in this context are aberrant and bloody supply is not uniform. 
The key trigger of angiogenesis is the need of oxygen in hypoxic tissues. Hypoxia 
results in the increase of Reactive Oxygen Species (ROS) that triggers the production of 
Hypoxia Inducible Factor α (HIF-α), which in turn causes the secretion of Vascular 
Endothelial Growth Factor-A (VEGF-A). The increase of VEGF-A levels breaks the 
balance between stimulating and inhibiting molecules and results in the so-called 
angiogenic switch (Adair and Montani, 2010). 
The most important proangiogenic factors belong to VEGF, Angiopoietin, 
Platelet-Derived Growth Factor (PDGF) and Fibroblast Growth Factor (FGF) families. 
Other molecules can be involved, such as Transforming Growth factor β (TGF-β), 
Hepatocyte Growth Factor (HGF), Insulin-like Growth Factor (IGF), Interleukin 8 (IL-
8), Placental Growth Factor (PlGF), and many others (Carmeliet and Jain, 2000). 
Among the inhibiting molecules, the most relevant ones are Trombospondin-1 
and 2 and the statins, such as Angiostatin, Endostatin and Vasostatin (Carmeliet and 
Jain, 2000). 
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1.1 Physiological angiogenesis 
The two main physiological mechanisms of angiogenesis are called sprouting 
angiogenesis and intussusceptive angiogenesis, depending on the way vessels form 
(picture 1). Sprouting angiogenesis forms blood vessels starting from sprouts of 
endothelial cells to provide vessel-free tissues with vasculature. On the other hand, 
intussusceptive angiogenesis occurs to expand the existing vascular network through a 
splitting process. 
In physiologic conditions, angiogenesis is a well-coordinated process, but that 
often results in a complex network of vessels, in which some of them are ‘useless’. 
Remodeling of vasculature occurs to prune the redundant vessels and to mature the 
remaining ones. 
 
 
 
 
 
 
 
1.1.1 Sprouting angiogenesis 
Sprouting angiogenesis is a quite known mechanism since it was discovered about 200 
years ago (Adair and Montani, 2010). The term “sprouting” derives from the sprouts of 
endothelial cells that originate from a pre-existing vessel. These sprouts grow in 
response to an increasing gradient of VEGF-A, that is secreted by hypoxic cells (picture 
2a). Hypoxic cells also secrete Angiopoietin-2 (Ang2), which detaches pericytes from 
endothelium thanks to its bond to its receptor Tie2.  
Endothelial cells that are exposed to high concentrations of VEGF-A are selected 
to become tip cells (picture 2b). A tip cell is an endothelial cell that guides the 
Picture 1. Basic types of primary vascular growth. Redrawn after Carmeliet and Collen, 2000 (Adair and 
Montani, 2010). 
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formation of new vessels and is morphologically characterized by cellular processes 
called filopodia. 
Delta-like ligand 4 (Dll4)-Notch pathway is essential for tip cell selection. Dll4 
expression is induced on cells exposed to VEGF. Dll4 binds to Notch receptor on 
neighbouring cells causing its proteolytic cleavage. In this way, cleaved Notch 
intracellular domain (NICD) goes to the nucleus to decrease Vascular Endothelial 
Growth Factor Receptor 2 (VEGFR2) and Neuropilin 1 (Nrp1) expression, that are 
essential for tip cell phenotype. On the other hand, NICD increases Vascular 
Endothelial Growth Factor Receptor 1 (VEGFR1) expression, which traps VEGF 
making the neighbouring cells less responsive to it (Welti et al., 2013). The cells with 
VEGF-induced expression of Dll4 and VEGFR2 gain the motility and the 
morphological characteristics of the tip cells, while the cells in which Notch signaling is 
activated and are less responsive to VEGF-A become stalk cells (Carmeliet et al., 2009). 
The sprouting angiogenesis process starts with the enzymatic degradation of 
capillary basement membrane thanks to matrix metalloproteinases secreted by 
filopodia on tip cells. Filopodia are also enriched with VEGFR2, which allow tip cells to 
sense the increasing gradient of VEGF and to lead the sprout (picture 2c). The 
contraction of actin filaments allows filopodia to invade tissues towards the higher 
concentration of VEGF. 
 
 
 
 
 
 
 
 
 
 
 
VEGF VEGF VEGF VEGF 
Picture 2. Formation of new vessel branches through sprouting angiogenesis (modified from Carmeliet et 
al., 2009). 
 
Introduction 
18 
 
Behind tip cells, stalk cells proliferate to elongate the nascent sprout (picture 2d). 
Meanwhile, vacuoles inside of them grow and converge to create the lumen of the 
vessel. When two tip cells from different sprouts meet, they fuse to connect the 
newborn vessels (picture 2e) and create a lumen in which oxygenated blood can flow 
(picture 2f). 
Finally, newborn vessels are surrounded by pericytes and extracellular matrix 
(picture 2g), and endothelial cells assume a quiescent “phalanx” phenotype (picture 
2h). 
 
1.1.2 Intussusceptive angiogenesis 
Intussusceptive angiogenesis consists in the formation of a vascular wall into the 
lumen of pre-existing vessels and for this reason it is also called splitting angiogenesis. 
In comparison with sprouting angiogenesis, intussusceptive angiogenesis is a 
faster and more efficient process because it is not based on cell migration and 
proliferation, but on the formation of transcapillary tissue pillars that split the vessel 
into two (Risau, 1997).  
It occurs to divide large vessels into smaller ones to create bifurcations in arteries 
or veins, or to prune inefficient vessels. It seems to be mostly determined by shear 
stress, which is the force applied by blood flow on endothelial cells (Mentzer and 
Konerding, 2014). 
The process begins with the protrusion of opposing endothelial cells into the 
capillary lumen until they touch each other and establish cell-to-cell junctions. The 
endothelial bilayer and basement membranes are perforated centrally to permit the 
entrance of growth factors and the migration of fibroblasts and pericytes. These cells 
finally produce collagen and other components of ECM in order to form the tissue 
pillar (Mentzer and Konerding, 2014). 
 
1.1.3 Remodeling 
The vascular network that results from sprouting or intussusceptive angiogenesis is 
often enriched in redundant and poorly perfused vessels that need to be eliminated. 
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The process with which useless vessels regress to form a mature and more functional 
vascular plexus is known as remodeling. 
Very little is known about this process so far. It is known that one of the leading 
causes of remodeling is shear stress, which is the force that blood flow applies on 
endothelium walls. Flow can promote the maturation of the endothelium through the 
proliferation of endothelial cells, the reorganization of the junctions between them and 
the deposition of extracellular matrix. In this sense, high blood flow leads to 
maturation, whereas poor perfusion promotes vessel regression (Carmeliet, 2003).  
Recent studies on mouse retinas showed that endothelial cells adapt their 
morphology, patterns of gene activity and polarity (i.e. the relative position of the 
nucleus and the Golgi) in response to shear stress. In particular, endothelial cells 
change their polarity in order to polarize against blood flow and to counteract its 
action (Franco et al., 2015). 
As said, remodeling essentially consists in vascular regression, which does not 
occur by apoptosis but by active migration of endothelial cells to neighbouring vessels 
(Franco et al., 2015). In particular, endothelial cells migrate from vascular segments 
with low or oscillatory flow to high-flow ones nearby. As a conclusion, low-flow 
branches regress and high-flow ones are stabilized. 
Recent studies have demonstrated that remodeling in mouse retinas is negatively 
regulated by non-canonical Wnt signaling, a pathway that is known to be involved in 
the establishment of planar cell polarity (Franco et al., 2016). The loss of this pathway 
causes enhanced sensitivity to lower shear stress and therefore in earlier vascular 
regression and accelerated remodeling. 
 
1.2 Tumor angiogenesis 
The ability of forming new blood vessels is one of the ten hallmarks of cancer, in 
addition to sustaining proliferative signaling, evading growth suppressors, resisting 
cell death, enabling replicative immortality, activating invasion and metastases, 
genome instability and mutations, avoiding immune destruction, tumor-promoting 
inflammation and deregulating cellular energetics (Hanahan and Weinberg, 2011). 
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The first observation about how tumors and angiogenesis are strictly correlated 
was made in early 1900s (Goldmann, 1907), but the first scientist that hypothesized that 
tumors are dependent on blood supply was Judah Folkman in 1971. He observed that 
when tumors reach 2-3 mm in diameter, endothelial cells activate and proliferate to 
form new capillaries. This phenomenon can be explained by the fact that below that 
dimension, gases and nutrients can be distributed by diffusion. If blood supply is not 
provided, masses cannot grow further (Folkman, 1971). 
The formation of blood vessels in the tumor context can occur by the active 
recruitment of angioblasts from the bone marrow or by co-opting the existing 
vasculature (Carmeliet and Jain, 2000). In the first case, the tumor is completely 
avascular and forms de novo blood vessels by vasculogenesis. In the second case, it co-
opts the host vascular network, but the co-opted vessels start soon to regress as a 
mechanism of defense. As a consequence, the tumor mass is deprived of oxygen, it 
becomes hypoxic and produces VEGF, forming its own vasculature by sprouting or 
intussusceptive angiogenesis (Yancopoulos et al., 2000). 
Now it is widely known that angiogenesis starts when the ‘angiogenic switch’ 
occurs, that is when pro-angiogenic signals exceed anti-angiogenic ones (picture 3; 
Bouck et al., 1996). These signals can be molecular (e.g. members of VEGF and 
Angiopoietin families), mechanical (e.g. pressure from proliferating cells), metabolic 
(e.g. low pO2), genetic (e.g. loss or gain of function of molecules involved in 
angiogenesis) or immune/inflammatory factors (Carmeliet and Jain, 2000). 
In comparison with physiological angiogenesis, the expression of molecules that 
stimulate or inhibit the formation of new vessels is not well-coordinated in tumors. 
This leads to the growth of abnormal vessels, which may lack pericytes and have 
fenestrations. They can also have tumor cells among endothelial cells creating ‘mosaic 
vessels’, or there even can be vessels made by cancer cells (the so-called vasculogenic 
mimicry). They can have too many branches or shunts, or be tortuous or with uneven 
diameters. The structure can be so abnormal that the definition of arteries, capillaries 
and veins can be tricky (Lagenkamp and Molema, 2009). The presence of structural 
abnormalities and malformations leads to chaotic and variable blood flow that impairs 
oxygen and nutrient supply. Therefore, there are often areas of hypoxia and necrosis 
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within the tumor that may select more malignant and metastatic cells. Moreover, 
hypoxic tissues produce HIF-α that stimulates the production of VEGF, with the 
consequent inducement of the formation of new vessels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The ultrastructure of tumor vessels is also affected. In fact, they may present 
fenestrations, transcellular holes or vesicles that affect permeability. Abnormalities like 
these can result in hemorrhages and higher interstitial fluid pressure, which eventually 
limit perfusion (Carmeliet and Jain, 2011). Moreover, the base membrane may be 
discontinuous or absent, and endothelial cells may have an irregular shape and/or 
grow one on each other. All of these aspects have a great impact on vascular 
functionality and structure: tumor vessels are usually much leakier than normal 
vasculature and their permeability is considerably higher, even if these characteristics 
may vary between tumor type and after treatment (Carmeliet and Jain, 2000). 
The abnormal vascular structures found in tumors show high heterogeneity 
(table I). Six different types of tumor vessels have been identified. Four of the six vessel 
types (mother vessels, capillaries, glomeruloid microvascular proliferations, and 
vascular malformations) are formed by angiogenesis, starting from preexisting normal 
vessels, usually venules and capillaries. The two remaining ones (feeder arteries and 
draining veins) develop from a process called arterio-venogenesis. This mechanism is 
Picture 3. Schematic representation of angiogenic switch, which occurs when proangiogenic signals exceed 
antiangiogenic ones. When angiogenic switch occurs and new vessels are formed, dormant tumors start to 
proliferate and eventually may spread to other tissues (Gelao et al., 2013). 
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poorly understood, but it is known to involve the remodeling of preexisting arteries 
and veins (Nagy et al., 2010). 
 
Process 
involved 
Vessel type Vessel properties 
Angiogenesis 
Mother vessels (MV) 
Large, thin-walled, hyperpermeable, lightly fenestrated 
pericyte-poor sinusoids that are engorged with red blood 
cells. 
Capillaries 
Formed from MV by a process that involves intra-luminal 
bridging and intussusception. 
Glomeruloid 
microvascular 
proliferations (GMP) 
Poorly organized vascular structures that resemble renal 
glomeruli macroscopically. GMP are comprised of 
endothelial cells and pericytes with minimal vascular 
lumens and reduplicated basement membranes. 
Vascular 
malformations (VM) 
Mother vessels that have acquired an often-asymmetric coat 
of smooth muscle cells and/or fibrous connective tissue. 
Arterio-
venogenesis 
Feeder arteries (FA) Enlarged, often tortuous arteries and veins that are derived 
from preexisting arteries and veins. They extend radially 
from the tumor mass, supplying and draining the 
angiogenic vessels within. Draining veins (DV) 
 
 
From the molecular point of view, many proangiogenic factors are overexpressed 
in tumors. The first to be discovered was the fibroblast growth factor (FGF), but the 
most ubiquitous is VEGF-A. The other family members of VEGF-A (VEGF-B, VEGF-C 
and VEGF-D) are also present in tumors, as well as PlGF and Angiopoietins (Bergers 
and Benjamin, 2003). The abundance of angiogenesis-stimulating factors enhances the 
formation of new blood vessels.  
Many molecular mechanisms are involved in tumor angiogenesis. VEGF and 
angiopoietin family members have a predominant role. In particular, VEGF is the main 
driver of the formation of new vessels and it is often overexpressed, causing an 
abundance of vessel sprouts. On the other hand, the high expression of Angiopoietin 2 
(Ang2), which has a negative effect on vessel stability, causes failure in blood vessel 
maturation and integrity (Yancopoulos et al., 2000). 
The impaired balance of proangiogenic and inhibiting factors leads to up- or 
downregulation of adhesion molecules. For instance, they are upregulated by VEGF 
Table I. Classification of tumor vessels (Nagy and Dvorak, 2012). 
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and tumor-necrosis factor-α (TNF-α), whereas their presence decreases thanks to basic 
fibroblast growth factor (bFGF) and transforming growth factor-β1 (TGF-β1). The 
irregularity of distribution and expression of adhesion molecules, in addition to a 
chaotic blood flow, can lead to an impaired interaction with leukocytes on endothelium 
walls, causing a lower immune response (Jain et al., 1996). 
Irregular angiogenesis can also lead to the formation of blood vessels by tumor 
cells without the participation of endothelial cells. This phenomenon has been called 
vasculogenic mimicry (VM). It was first observed in melanoma, both in vivo and in 
vitro. In human invasive uveal melanoma specimens, vascular channel networks 
negative for endothelial markers were observed. These channels were absent in poorly 
invasive melanomas. Highly invasive melanomas conserved the ability to form 
vascular-like channels in vitro, in absence of endothelial cells or fibroblasts and without 
the addition of soluble growth factors such as bFGF, TGF-β, VEGF, PDGF. Moreover, 
the presence of these structures correlated with a poorer prognosis (Maniotis et al., 
1999). 
Vascular networks made of tumor cells stain negative for endothelial cell 
markers (such as Factor VIII-related antigen, Ulex, CD31, CD34, and KDR) but are 
positive for the staining of the periodic acid-Schiff (PAS) reagent, that dyes the 
basement membrane (Folberg et al., 2000). Interestingly, it has been observed that in 
melanoma these channels were rich in laminin, collagens IV and VI, and heparin 
sulfate proteoglycans, and contained plasma and red blood cells, indicating a perfusion 
(Kirschmann et al., 2012). Other characteristics that define VM are the presence of 
cancer cells that line the channels rather than endothelial cells, the expression of a stem 
cell-like phenotype, the presence of ECM remodeling, and the connection of the 
network with the tumor microcirculation system (Qiao et al., 2015).  
VM has been found in other tumor types, such as sarcomas (Ewing, mesothelial, 
synovial, osteosarcoma, alveolar rhabdomyosarcoma), carcinomas (breast, ovary, lung, 
prostate, bladder, kidney) and brain tumors (gliomas, glioblastoma, astrocytoma) 
(Kirschmann et al., 2012). 
Many molecular pathways have been associated with VM. One of them is linked 
to VE-cadherin, a transmembrane glycoprotein usually expressed by endothelial cells 
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that promotes homotypic cell-cell interactions. It also regulates EphA2 (erythropoietin-
producing hepatocellular carcinoma-A2) activity by mediating its ability to become 
phosphorylated through interactions with its ligand Ephrin-A1 (Kirschmann et al., 
2012). VEGF-A is important to sustain VM and to promote cell plasticity. Through its 
binding to the receptor VEGFR1 and the activation of the PI3K-Akt cascade, it is 
thought to mediate endothelial cell differentiation and organization into vascular 
tubes. In melanoma cells, VM seems to be triggered by the synergic action of 
VEGFR1/VEGF-A/PI3K/PKCα and integrin-signaling pathways (Cheng et al., 2003). 
In breast cancer cells, high expression of COX-2 (cyclo-oxygenase 2) correlates 
with the presence of VM networks (Kirschmann et al., 2012). COX-2 induces the release 
of VEGF and activates the endothelial cells through the production of eicosanoids 
(Gately, 2000).  
In general, cell plasticity is important for the establishment of VM. Many studies 
have reported that VM is linked with stemness and epithelial-mesenchymal transition 
(EMT) (Qiao et al., 2015; Liu et al., 2016). The presence of cancer stem cells (CSCs) has 
been linked with VM in many tumor types, such as leukemia, oral squamous cell 
carcinoma, melanoma, glioblastoma (Qiao et al., 2015). 
Since CSCs have been linked to drug resistance and CSCs induce VM, the 
presence of VM may affect the response to anti-cancer treatments. Indeed, anti-
angiogenic drugs reduce the tumor vasculature and increase hypoxia, forcing the CSCs 
to differentiate into endothelial-like cells and forming VM. Therefore, drugs targeting 
VM and EMT have to be studied to overcome recurrence and drug resistance (Liu et al., 
2016). 
 
 
2. Mammary carcinoma 
Breast cancer is the most frequent type of cancer that affects women. Every year, about 
50,000 patients are diagnosed with breast cancer in Italy, representing the 28% of all 
female tumors. It is also the first leading cause of cancer death in women in Italy, 
killing about 12,000 patients every year (AIOM, 2017). 
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Breast cancer cannot be considered as a unique disease, but as a heterogeneous 
group of many subtypes with different characteristics from the molecular, histological 
and clinical point of view (Dawson et al., 2013). These differences between subtypes 
must be taken into account for the choice of the proper therapy and to establish the 
correct prognosis. 
From the histopathological point of view, the majority (about 70-80%) of breast 
cancers is classified as invasive ductal carcinomas. The remaining ones can be 
described as lobular, tubular, medullary or metaplastic carcinomas (Ellis, 2003). Tumor 
grade assessment, based on the level of differentiation and on the proliferative index 
(Ki67 score) of the mass, is also implemented to define the biologic characteristics of 
the tumor and to predict the clinical behavior. 
Immunohistochemical techniques (IHC) are also used to classify mammary 
carcinomas based on their expression of the hormone receptors (HR, that are the 
estrogen receptor and the progesterone receptor) and of the Human Epidermal growth 
factor Receptor 2 (HER2, see paragraph §2.1). Therefore, there can be many 
possibilities: triple-positive (HR+/HER2+), luminal A, luminal B, HER2+, HR+/HER2-, 
HER2+/HR-, triple-negative (HER2-/HR-). 
Another way to classify breast cancer is based on the PAM50 assay, a Real Time 
qPCR-based test that analyzes the expression of 50 genes and identifies four main gene 
expression signatures. Overlapping the results from the ICH-based classification with 
the one based on the PAM50 assay, four subtypes can be identified, even if some 
discordance is present (table II): luminal A, luminal B, basal-like and HER2-enriched 
(Prat et al., 2015). 
 
IHC-based group N 
PAM50 intrinsic subtype distribution 
Luminal A Luminal B HER2-enriched Basal-like 
HR+/HER2- 4295 60.3% 31.9% 6.6% 1.2% 
Luminal A 637 62.2% 27.0% 10.2% 0.6% 
Luminal B 317 34.1% 51.1% 11.0% 3.8% 
HER2+ 831 17.6% 26.8% 44.6% 11.0% 
HER2+/HR+ 182 33.0% 46.2% 18.7% 2.2% 
HER2+/HR- 168 19.0% 4.2% 66.1% 10.7% 
TNBC 868 1.6% 3.2% 9.1% 86.1% 
 
Table II. Distribution of the PAM50 intrinsic subtypes within the pathology-based groups (Prat et al., 2015). 
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The luminal subtypes represent the vast majority of mammary carcinomas (about 
75% of all breast cancers), and are characterized by the expression of estrogen (ER) 
and/or progesterone (PR) receptors, and the lack of HER2 overexpression (Yersal and 
Barutca, 2014). Compared to the other subtypes, they also have the best prognosis, due 
to their sensitivity to the chemotherapy and also to the hormone therapy, including 
tamoxifen and the aromatase inhibitors (Tang et al., 2016). The main difference between 
the luminal A and luminal B subtypes lies in the different proliferative index: in fact, 
Ki67 positivity is higher in luminal B breast cancers (>14%). They also differ in the 
response to therapies: luminal A subtype is usually more responsive to endocrine 
treatments, whereas luminal B one responds better to chemotherapy (Tang et al., 2016). 
This difference is probably due to the fact that luminal B tumors usually have a lower 
expression of PR (Prat et al., 2015). The relapse rate is usually higher in patients with 
luminal B subtype (Yersal and Barutca, 2014), often due to the presence of a higher 
number of mutations (Prat et al., 2015). 
The basal-like subtype is the most aggressive subtype, and represents the 10-15% 
of all breast cancers. It is also called triple-negative, because it lacks the expression of 
HER2 and of both hormone receptors. For this reason, it is not eligible for targeted 
therapy. Usually, basal-like carcinomas are treated with taxanes, anthracyclines, 
platinum-based chemotherapy and poly ADP ribose polymerase (PARP) inhibitors. 
The risk of primary or secondary resistance and of recurrence is very high, and the 
level of aggressiveness of this subtype is also more elevated than in the other subtypes. 
These tumors usually have a high expression of proliferation-related genes and 
keratins, which are mostly expressed by the basal layer of the skin. They also present a 
high number of mutations across the genome (Prat et al., 2015). For these reasons, the 
prognosis is usually poorer (Tang et al., 2016). Among the basal-like subtype, some 
breast cancers can be classified as claudin-low. This subtype includes those triple-
negative carcinomas that have a low expression of tight junction proteins and of cell-to-
cell adhesion molecules (such as claudins, occludin and E-cadherin), and show 
epithelial-mesenchymal transition and stem cell features. The clinical outcome is also 
poor, like other basal-like cancers (Yersal and Barutca, 2014). 
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The HER2-enriched subtype represents about 15-20% of all breast cancers and is 
characterized by the overexpression of the receptor HER2. It is characterized by the 
highest number of mutations across the genome (Prat et al., 2015). According to the 
American Society of Clinical Oncology (ASCO) and the College of American 
Pathologists (CAP) guidelines, the standardized test to determine if HER2 is 
overexpressed is the Hercep Test™ and is based on IHC. This overexpression is usually 
due to the amplification of the gene that can be detected by FISH (Fluorescence In Situ 
Hybridization). 
The Hercep Test™ provides a score of positivity ranging from 0 to +3. The score 0 
defines a negative sample; a score +1 corresponds to a negative sample with a barely 
perceptible positivity with incomplete membrane staining in less than 10% of the 
tumor cells; a +2 sample is classified as weakly positive, with moderate complete 
membrane staining in more than 10% of the cells; finally, a +3 sample displays a strong 
and complete membrane staining in more than 10% of the tumor cells. Samples 
classified as 2+ also undergo the FISH analysis to detect the amplification of the gene 
(Dako Hercep Test™ Manual). The amplification of the HER2 gene is classified as 
positive if the HER2 copy number is higher than 4 or the HER2/centromere of 
chromosome 17 ratio is higher than 2 (Wolff et al., 2013). 
Compared to luminal subtypes, the abundance of HER2 confers higher 
aggressiveness to the tumor, but lower than basal-like subtype. Usually HER2-positive 
breast cancers have high proliferative index. 75% have a high histological and nuclear 
grade. Moreover, they often have p53 mutations, and about half of them are positive 
for ER, even if they generally express low ER levels (Yersal and Barutca, 2014). Despite 
their intrinsic malignity, the prognosis has been improved by the introduction of 
HER2-targeted drugs such as trastuzumab in clinical practice (see paragraph §2.3.1). 
 
2.1 HER2 
The proto-oncogene HER2, also known as ErbB2, is a tyrosine kinase (TK) receptor that 
belongs to the ErbB family. Its gene is localized on chromosome 17 (17q12) and 
encodes for a 185 kD protein that has three main domains: an extracellular domain 
(composed by two ligand-binding domains and two cysteine-rich regions), a 
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transmembrane domain and an intracellular domain (that includes a carboxy-terminal 
tail rich in tyrosine residues, and a tyrosine-kinase domain). 
Like the other TK receptors, in absence of the ligand the receptors of ErbB family 
are in a monomeric form and in a close and inactive conformational status, in which 
the two cysteine-rich regions are in contact with each other and with the carboxy-
terminal tail that keeps the tyrosine-kinase domain inactivated. The binding with the 
ligand causes the opening of the monomer and the separation of the two cysteine-rich 
regions. One of the latter is called dimerization arm, because it gets in contact with the 
dimerization arm of another monomer. The dimerization of the two receptors changes 
the conformational structure of the receptor and causes the extrusion of the carboxy-
terminal tail. Consequently, the activation of the tyrosine-kinase domain triggers the 
trans-phosphorylation of the tyrosine residues on the carboxy-terminal tail of the other 
monomer. The phosphorylated tyrosine residues can be bound by numerous molecules 
involved in many intracellular signaling pathways, including survival, proliferation 
and invasivity (Burgess et al., 2003). 
Unlike the other members of the ErbB family (i.e. Epidermal Growth Factor 
Receptor – EGFR, HER3 and HER4), HER2 does not have a known ligand, and it is 
always in a constitutively open conformation (Cho et al., 2003). Therefore, there is no 
need of the binding with a ligand to trigger signaling cascades. 
The role of HER2 on human physiology lies in the correct formation of the 
cardiac trabeculae and of the cranial neural crest during embryonic development (Lee 
et al., 1995). After birth, it is important for the early stages of the mammary 
morphogenesis: conditional knock-out murine models for HER2 showed defects in the 
elongation and the ramification of the mammary ducts, but with little impact on the 
capability to lactate (Andrechek et al., 2005). 
The overexpression of this receptor in tumors was discovered in 1985 by Axel 
Ullrich at Genentech, CA, USA (Coussens et al., 1985). HER2 was found to have strong 
molecular analogies with EGFR and the same chromosomal location of the rat 
oncogene neu, that had been previously associated with glioblastoma (Schechter et al., 
1984). In 1989, Slamon and colleagues observed that HER2 was overexpressed in 25-
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30% of human mammary carcinomas and it was also implicated in the pathogenesis of 
human ovarian cancers (Slamon et al., 1989). 
HER2 was later found to be overexpressed in other cancer types: 6-35% of non-
small cell lung cancers (Mar et al., 2015), 6-29.5% of gastric carcinomas (Boku, 2014), 2-
66% of ovarian cancers (Hodeib et al., 2015), 11% of esophageal carcinomas (Zhang et 
al., 2016), 35.5% of salivary duct carcinomas (Ettl et al., 2012), 17-33% of uterine cancers 
(Diver et al., 2015), 14% colon cancers (Drecoll et al., 2014) and 28-85% of bladder 
carcinomas (Zhao et al., 2015). 
HER2 can form homodimers, but preferentially forms heterodimers with the 
other members of the ErbB family or with different receptors. Several pathways can be 
activated according to the heterodimer that is formed (Moasser, 2007). As 
schematically represented in picture 4, these pathways lead to enhanced proliferation, 
cell motility, higher invasivity, resistance to apoptosis and angiogenesis (Arteaga et al., 
2011). 
In general, the overexpression of HER2 changes the composition of dimers 
between HER family members. The number of HER2-containing dimers and HER2 
homodimers increases, deregulating cell polarity and cell adhesion and causing 
prolonged signaling activity that can evade signal attenuation mechanisms. As a result, 
the potency of signaling is much higher in HER2-positive tumors (Moasser, 2007). 
Higher survival and proliferation are the major effects of the signaling of HER2. 
These effects are driven by the activation of PI3K (Phosphatidyl-Inositol 3 Kinase)-Akt 
and Ras-Raf-MAPK (Mitogen-Activated Protein Kinase) pathways. Proliferation and 
survival are also the consequences of the deregulation of the G1/S checkpoint in the cell 
cycle through the increase of cyclin D1, cyclin E and cdk6 (cyclin-dependent kinase 6) 
and the degradation of p27kip1, a cyclin-cdk complex inhibitor (Moasser, 2007). 
The heterodimers formed by HER2 and HER3 are very stable and active from the 
transductional point of view. Like HER2, HER3 is a functionally incomplete receptor, 
because it lacks the binding site for ATP in its catalytic domain. Therefore, HER3 is 
functionally inactive and needs to heterodimerize to trigger signaling cascades (Berger 
et al., 2004). The formation of HER2-HER3 heterodimers causes the enhancement of 
survival and cell proliferation, through the activation of Erk that is activated through 
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the Ras-Raf pathway. This leads to the activation of numerous nuclear targets, 
including Elk1, PEA3, Sp1, AP1 and c-Myc. Another signaling pathway activated by 
the dimer HER2-HER3 is the PI3K-Akt cascade, that leads to higher anti-apoptotic 
signals and enhanced survival due to the inhibition of proapoptotic molecules such as 
Bad, GSK3 and the transcription factor FKHR-L1. Moreover, the activation of PLCγ 
and JAK-STAT pathways promotes cell proliferation through the activation of cyclin 
D1 (Citri et al., 2003). 
On the other hand, EGFR-HER2 dimers lead to the activation of MAPK and PI3K 
pathways, resulting in higher invasivity and in the deregulation of cell cycle. 
Moreover, these dimers are very stable, and their formation blocks the internalization 
and the degradation of EGFR that is normally activated by the binding of the ligand 
and the homodimerization. In this way, the proliferative and pro-invasive stimuli due 
to the dimerization between HER2 and EGFR last more (Moasser, 2007). 
HER2 homodimers interact with the Par3-Par6-aPKC-CDC42 complex, causing 
its disruption that leads to the delocalization of proteins involved in cell polarity and 
adhesion, such as gp135, ZO-1 (Zonula Occludens 1) and E-cadherin (Aranda et al., 2006; 
Moasser, 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Picture 4. Schematic representation of the signaling pathways activated by the HER family members, 
according to the dimers formed (Moasser, 2007). 
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2.1.1 HER2 isoforms: Δ16 
Many molecular alterations of HER2 have been identified both in human proto-
oncogene HER2 and in rat neu. The origin of these alterations may be due to somatic 
mutations or post-transcriptional or post-translational modifications. In neu, somatic 
mutations are prevalent, whereas in human breast cancer mutations on HER2 gene are 
extremely rare. In fact, the alterations of human HER2 are mostly caused by 
modifications of the transcript or by proteolytic cleavage of the protein (Moasser, 2007; 
Arribas et al., 2011). 
One of the most important variant of HER2 is the alternative splicing isoform 
Δ16. Its name is due to the in-frame deletion of exon 16 (picture 5). This splice isoform, 
which is exclusively present in tumors, represents about the 8.6-9.9% of the total 
transcript of HER2 (Castiglioni et al., 2006; Mitra et al., 2009). It is present in 52% of 
HER2-positive mammary carcinomas and in 89% of locally disseminated ones (Mitra et 
al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Δ16 was first discovered by Kwong and Hung in cancer cell lines in 1998. They 
found a splicing variant of HER2 lacking 48 bp coding for 16 amino acids, which were 
localized in the juxtamembrane region of the receptor. This variant showed enhanced 
Picture 5. Schematic representation of the Δ16 (referred as delta16HER2) alternative splice form of the 
human HER2 gene with an in-frame deletion of exon 16 (Ghedini et al., 2013).  
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ligand-independent signaling activity and higher transforming capability than those of 
HER2 (Kwong and Hung, 1998; Siegel et al., 1999). 
The lack of exon 16 causes the removal of two cysteines disrupting two disulfide 
bonds and changing the conformational structure of the receptor (picture 5). In this 
way, two cysteine residues are left unpaired and, therefore, they are free to form 
intermolecular bonds. The dimers that form in this way are mainly homodimers and 
they are more stable, more active and more numerous compared to the full-length 
isoform (Mitra et al., 2009). 
Overall, the Ras-Raf-MAPK and PI3K-Akt signaling pathways are more activated 
by Δ16 than full-length HER2, leading to higher invasivity and migration in vitro 
(Mitra et al., 2009; Alajati et al., 2013). Moreover, Alajati and colleagues found that Src 
kinase is more activated and co-localized with Δ16 in Δ16-transfected MCF-7 cells, 
whereas Src is inactive and localized in the perinuclear region in HER2-transfected 
MCF-7 cells (Alajati et al., 2013). 
Δ16 also shows higher invasivity and tumorigenicity in vivo. When transfected 
with Δ16, different cell lines (HEK293, NIH 3T3, MCF-10A) showed a higher incidence 
of tumors formed when injected in mice, in comparison with full-length HER2 
(Castiglioni et al., 2006; Alajati et al., 2013). Alajati and colleagues also proved that the 
metastatic burden to the lungs is higher when injecting Δ16-transfected MCF-7 cells 
intravenously or orthotopically rather than HER2-transfected ones (Alajati et al., 2013). 
At the beginning, the isoform Δ16 had been linked to trastuzumab resistance in 
vitro, due to a decreased binding to this antibody (Castiglioni et al., 2006; Mitra et al., 
2009). Mitra and colleagues analyzed the activation of the PI3K suppressor PTEN 
(Phosphatase and TENsin homolog), and they found that it is dephosphorylated and 
therefore activated in HER2-transfected MCF-7 cells treated with trastuzumab. The 
activation of PTEN caused a 50%-decrease in the proliferation rate in these cells, due to 
the cytostatic effect of the drug. In Δ16-trasfected cells, instead, PTEN was 
phosphorylated and therefore inactive, and the proliferation rate and the ability of 
forming colonies were unaltered in comparison with untreated cells (Mitra et al., 2009). 
However, three groups of researchers have recently proved that Δ16-positive 
tumors are sensitive to trastuzumab in vivo. In particular, Alajati and colleagues 
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observed that the tumors derived from the in vivo injection of the cell line MCF-10A, 
previously transfected with Δ16, were sensitive to this drug in terms of inhibition of 
tumor growth and of cell proliferation (Alajati et al., 2013). A study performed by the 
Laboratory of Immunology and Biology of Metastases (University of Bologna, Italy), 
where this thesis was developed, and the Istituto Nazionale dei Tumori (Milan, Italy), 
also demonstrated that patients with HER2-positive breast cancers responded better to 
trastuzumab if their tumors co-expressed activated Δ16 homodimers and 
phosphorylated Src, showing a functional relationship between them. This result 
confirmed what they observed in tumors of Δ16-transgenic mice, in which Δ16 was 
optimally activated through the activation of Src (Castagnoli et al., 2014). In a very 
recent article by the team of researchers at the Laboratory of Immunology and Biology 
of Metastases, trastuzumab was effective in preventing or delaying the tumor onset in 
Δ16-transgenic mice. Moreover, Δ16-expressing cells resulted sensitive to trastuzumab 
in 3D-culture, while HER2-expressing ones showed resistance (Palladini et al., 2017). 
A strict correlation between Δ16-driven aggressiveness and stemness was 
recently found: cancer cell lines derived from spontaneous mammary tumors of Δ16-
transgenic mice had higher expression of Notch, Wnt and epithelial-mesenchymal 
transition-related genes, compared to cell lines derived from tumors of full-length 
HER2-transgenic mice. Moreover, the stem-like population of CD29high/CD24+/Sca-1low 
cells was more abundant and they showed greater in vivo ability to engraftment in 
serial dilution conditions (Castagnoli et al., 2017). 
Δ16 has been recently linked to de novo resistance to the TKI inhibitor lapatinib 
and acquired resistance to the selective Src inhibitor saracatinib, but Δ16-driven breast 
carcinogenesis can be completely suppressed by the irreversible small molecule pan-
HER inhibitor dacomitinib (Tilio et al., 2016). 
 
2.2 HER2 and tumor angiogenesis 
HER2 has an active role in tumor angiogenesis. Preclinical and clinical studies have 
pointed out that the activation of HER2 leads to an increase of pro-angiogenesis factors 
(Alameddine et al., 2013). 
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In a cohort study that involved 611 patients with HER2-positive breast 
carcinoma, a positive association between HER2 and VEGF expression was observed. 
Moreover, the simultaneous expression of HER2 and VEGF correlates with a poorer 
prognosis (Konecny et al., 2004). 
Alameddine and colleagues have discovered that cell lines that overexpress 
HER2 had a high expression of VEGF, COX-2 and HIF-α. VEGF was more elevated 
when HER2 dimerizes with EGFR or HER3 (Alameddine et al., 2013). 
The increase in expression of pro-angiogenic factors is mediated by the activation 
of PI3K-Akt and MEK-ERK pathways (picture 6). Downstream, the activation of 
mammalian target of rapamycin (mTOR) leads to the activation of the p70S6k kinase, 
which promotes the translation of the VEGF (picture 6.I) and HIF (picture 6.II) mRNAs 
(Klos et al., 2006). On the other hand, the activation of MAPK pathway promotes the 
transcription of the VEGF gene (picture 6.III). 
The third angiogenesis-related target of the activation of HER2 is COX-2 
(Moasser, 2007; Alameddine et al., 2013). Through receptor-mediated endocytosis, 
HER2 is internalized and translocated into the nucleus where, thanks to its kinase 
activity, directly bonds and activates the COX-2 promoter (picture 6.IV). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Picture 6. Angiogenesis-related pathways activated by HER2 (Alameddine et al., 2013): induction of 
VEGF (I) and HIF-α (II) translation through PI3K/Akt and MEK/ERK pathways; induction of VEGF 
transcription through MAPK pathway (III); direct induction of COX-2 transcription through receptor-
mediated endocytosis (IV).  
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HER2 has been also linked to vasculogenic mimicry. Liu and colleagues observed 
this phenomenon in invasive breast cancer specimens, defined as CD31-negative/PAS-
positive vessel-like structures with or without red blood cells inside. According to their 
observations, vasculogenic mimicry was more present in HER2-positive samples. 
Moreover, the number of vascular-like channels was more abundant in 3+ HER2-
positive carcinomas compared to 2+ or 0/+1 samples. A positive correlation between 
HER2 and vasculogenic mimicry was confirmed in vitro by comparing the number of 
vessel-like structures formed by MCF-7 cells transfected with HER2 and seeded on 
Matrigel: this number was higher compared to parental cells (Liu et al., 2013). 
 
2.3 Anti-HER2 targeted drugs in mammary carcinoma 
As said, the overexpression of HER2 confers higher malignity and increased 
aggressiveness to the tumor. However, the prognosis of the patients affected by HER2-
positive breast cancer has been improved thanks to anti-HER2 targeted drugs, both in 
terms of disease- or progression-free survival (DFS and PFS respectively) and overall 
survival (OS) (Gu et al., 2016). 
All carcinomas that are scored 3+ or 2+ but positive for HER2 amplification by 
FISH test are eligible for targeted therapy against HER2 (Wolff et al., 2013). 
 
2.3.1 Trastuzumab 
The standard therapy is based on trastuzumab (Herceptin®, Genentech), a humanized 
monoclonal antibody that binds the juxtamembrane region of HER2. This drug has 
been approved by FDA (Food and Drug Administration) in 1998 for metastatic HER2-
positive breast carcinoma and in 2006 for early stage HER2-positive breast carcinoma, 
both in adjuvant and neo-adjuvant settings (Tagliabue et al., 2011). 
In adjuvant setting, trastuzumab is administered after chemotherapy, or in 
association with taxanes after doxorubicin and cyclophosphamide-based therapy, or in 
association with carboplatin and docetaxel (Arteaga et al., 2011). 
In neo-adjuvant setting, trastuzumab is administered in association with 
chemotherapy for patients with locally advanced breast cancer or early stage breast 
Introduction 
36 
 
carcinoma. For patients with metastatic HER2-positive breast cancer, trastuzumab is 
administered alone or associated with paclitaxel or docetaxel (Arteaga et al., 2011). 
The major problem regarding the safety of trastuzumab is cardiotoxicity, but all 
adverse effects are usually treatable and largely reversible (Arteaga et al., 2011). 
The mechanisms of action of trastuzumab are many (picture 7), with a cytostatic 
or a cytotoxic effect. The mechanisms with a cytostatic effect are the inhibition of 
receptor dimerization, the inhibition of HER2 extracellular domain proteolytic cleavage 
and the consequent inhibition of activated p95-truncated HER2 receptor and the 
inhibition of tumor angiogenesis. On the other hand, the cytotoxic effects involve the 
antibody-dependent cell-mediated cytotoxicity (ADCC) and the inhibition of DNA 
repair (Tagliabue et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Trastuzumab binds the domain IV of HER2 (Parakh et al., 2017), causing the 
inhibition of dimerization by steric hindrance. If HER2 cannot dimerize, the signal 
pathways downstream are not activated, affecting proliferation. Cell cycle arrest in G1 
phase is also induced, because HER2 is not able to downregulate the cyclin-dependent 
Picture 7. Mechanisms of action of trastuzumab (modified from Spector and Blackwell, 2009). 
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kinase inhibitor p27Kip1 anymore. Apoptosis can also be induced through the 
upregulation of p53 (Spector and Blackwell, 2009). 
The binding of trastuzumab also inhibits the cleavage of the extracellular domain 
(ECD) of HER2, preventing the formation of the truncated form p95, that has been 
linked to higher malignity and a poorer prognosis (Arribas et al., 2011). This ECD-
lacking isoform is more active because it can homodimerize in a more stable way 
thanks to five cysteine residues that can form disulphide bonds between two different 
molecules. p95 homodimers activate numerous signaling pathways (MAPK, Akt, Src 
and PLCγ) that increase the expression of pro-metastatic proteins such as MMP1, 
Angiopoietin-like 4, MET, CD44, PLAUR, EphA2, ITGA2, ITGFB, TGF-α and 
interleukin-11 (Pedersen et al., 2009). 
Tumor angiogenesis is inhibited too, causing hypoxia to the tumor. In vitro, the 
treatment with this antibody leads to a decreased expression of VEGF, Angiopoietin-1, 
TGF-α and PAI-1 (Plasminogen Activator Inhibitor 1), and an increased expression of 
the anti-angiogenic factor TSP-1 (Thrombospondin 1) (Izumi et al., 2002). 
In addition to the previous ones, another cytostatic mechanism of action of 
trastuzumab involves the internalization and the consequent downregulation of HER2, 
through c-Cbl-mediated ubiquitination. However, this process seems to occur only 
after a prolonged exposure to trastuzumab (Baselga et al., 2001). 
Among the cytotoxic effects, the ADCC is the most relevant one. This mechanism 
does not depend only on the drug, but also involves the immune system of the patient. 
It consists in the interaction between the Fc portion of trastuzumab and the FcγRIIIA 
receptors on NK cells, macrophages and dendritic cells. The binding activates these 
cells, which will finally mediate the tumor cell death or involve CD8+ cytotoxic T cells 
(Kohrt et al., 2012). 
Besides ADCC, other immunologic mechanisms are involved in the therapeutic 
response to trastuzumab: complement-dependent cytotoxicity; antibody-dependent 
cellular phagocytosis (phagocytosis of monoclonal antibody-opsonized debris of target 
cells through receptors for the Fc portion of IgG of dendritic cells and macrophages); 
immune complex (monoclonal antibody and tumor antigen) uptake by antigen-
presenting cells (APCs); induction of a cross-talk among immune cells, including 
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natural killer cells and dendritic cells; induction of production of immunomodulatory 
cytokines (i.e. type I and type II interferons); induction of cross-presentation of tumor 
antigens by APCs and helper CD4+ T cells to cytotoxic CD8+ T cells, leading to priming 
of specific adaptive immune response such as tumor antigen-specific T lymphocyte 
response (Bianchini and Gianni, 2014). In general, in patients the major effects seem to 
be mediated by immunologic mechanisms. 
Finally, trastuzumab can interfere with the mechanisms of DNA repair through 
the inhibition of p21/WAF1, a protein involved in the cellular response to genomic 
damage (Spector and Blackwell, 2009). 
 
2.3.2 Mechanisms of resistance to trastuzumab 
Primary and secondary resistance to trastuzumab is one of the major problem in the 
clinical setting, affecting about 70% of patients with HER2-positive breast cancer 
(Parakh et al., 2017). The molecular mechanisms that have been proposed to explain 
drug resistance to trastuzumab are several. 
The first one concerns the modification of the target itself. If HER2 is altered, the 
drug binding might be compromised. In this case, the mutations involve the binding 
domain. One example is the p95 fragments that lack the extracellular domain but can 
activate the pathways downstream (Rexer and Arteaga, 2012). 
The binding site may not be accessible due to the steric hindrance mediated by 
membrane-associated glycoproteins such as MUC4, that co-localizes with HER2 when 
overexpressed. The cleaved form of MUC1 has been also found to have a role in 
masking the binding site of trastuzumab. However, the cleaved form of MUC1 can also 
homodimerize and activate proliferation and survival signaling pathways (Rexer and 
Arteaga, 2012). 
The ligand-dependent formation of heterodimers may be enhanced through the 
overexpression of EGFR and/or HER3, or of one of their ligands. This is consistent with 
the data regarding the inability of trastuzumab of preventing the ligand-dependent 
heterodimerization of HER2 (Rexer and Arteaga, 2012). 
Trastuzumab action can also be bypassed through the overexpression of 
molecular partners that do not belong to HER family, such as IGF1R or Met, that can 
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activate alternative pathways leading to increased proliferation and survival. The 
formation of IGF1R-HER2 dimers can potently activate PI3K/Akt pathway, whereas 
the dimerization with Met leads to the inhibition of the cell cycle inhibitor p27kip1 
(Arteaga et al., 2011; Puglisi et al., 2012). 
The activation of EphA2 has been linked to trastuzumab resistance too. In vitro 
studies have demonstrated that overexpression of this receptor confers resistance to 
trastuzumab, and the treatment with EphA2 blocking antibody restores sensitivity to 
the drug (Rexer and Arteaga, 2012). 
The trastuzumab-mediated inhibition of HER2 may have no effect if one of the 
downstream molecules is mutated to be constitutively activated. One example can be 
point mutation on the PIK3CA gene, which encodes the catalytic subunit p110α of 
PI3K, or on the gene of mTOR. Point mutations that inactivate PTEN have also been 
observed (Arteaga et al., 2011; Puglisi et al., 2012). 
A special mention goes to Src, which has been associated with overexpression of 
HER2 and trastuzumab resistance in breast cancer cell lines. The overactivation of Src 
has also been observed in patients whose tumors gained resistance to trastuzumab 
(Zhang et al., 2011). However, Castagnoli and colleagues found that the presence of 
Δ16 in tumors with activated Src confers higher sensitivity to trastuzumab (Castagnoli 
et al., 2014). 
In some cases, a downregulation of HER2 can be observed. In a clinical study 
reported by Mittendorf and colleagues, 8 patients with HER2-positive breast cancer out 
of 25 did not show a complete pathological response after the treatment with 
trastuzumab, due to the loss of HER2 overexpression (Mittendorf et al., 2009). 
Other mechanisms involve the alteration of proteins which have a role in 
regulating apoptosis or the cell cycle, such as the upregulation of cyclin E or the 
downregulation of p27kip1 (Rimawi et al., 2015). Moreover, elevated levels of the anti-
apoptotic proteins survivin and Mcl-1 have been found in HER2-overexpressing cell 
lines that are resistant to trastuzumab (Valabrega et al., 2011). 
As said, the major effect exerted by trastuzumab is mediated by the immune 
system of the patient through ADCC. Therefore, alterations in host factors with 
immunomodulatory functions can determine trastuzumab resistance. For example, 
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defects in FcγRIII or in the functionality of NK or macrophages are associated with 
poor response to trastuzumab in clinical and preclinical studies (Rexer and Arteaga, 
2012). Other immunological mechanisms of escape have been proposed, including the 
increase MHC class I expression on tumor cells by type I interferons and interferon γ, 
which can diminish the effect of NK cells by engaging inhibitory receptors, and impair 
cytotoxic T lymphocyte functions by non-classic MHC class I molecules (e.g., HLA-G). 
Type I interferons and interferon γ, in addition to the upregulation of oncogenic 
pathways, can also promote increased expression of PD-L1 protein in tumor cells, 
which inhibits activated T cells. The expression of PD-L1 and the costimulatory 
molecules CD80 and CD86 on dendritic cells may lead to the inhibition of the adaptive 
immune response. Moreover, T-cell-mediated immune responses can be decreased by 
the tumor-dependent downregulation of MHC class I molecules (Bianchini and Gianni, 
2014). 
Many strategies to overcome trastuzumab resistance have been proposed. 
Trastuzumab can be associated with hormone therapy, chemotherapy or other targeted 
drugs, such as lapatinib (a TKI that blocks the catalytic domain of EGFR and HER2), 
pertuzumab (a monoclonal antibody which binds another site on HER2 extracellular 
domain) or PI3K/Akt inhibitors. Another strategy consists in the modification of the 
trastuzumab itself, like trastuzumab-DM1, which is trastuzumab conjugated with a 
cytotoxic compound that blocks microtubule polymerization that is released in the 
cytoplasm when the drug is internalized into the cell (Rexer and Arteaga, 2012). 
 
2.3.3 Breast Cancer Stem Cells 
Another possible explanation about the mechanisms that drive drug resistance 
concerns the existence of a sub-population among cancer cells which is intrinsically 
resistant to treatments and can regenerate the tumor mass. These cells have stem-like 
properties, such as self-renewal and the ability to differentiate into several cellular 
types with reduced proliferative and differentiative potential. For these reasons, this 
population has been defined as Cancer Stem Cells (CSCs) (Korkaya and Wicha, 2013). 
The CSCs are present in many human tumor types, including breast cancer. The 
Breast Cancer Stem Cells (BCSCs) have been defined as cells with high expression of 
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CD44 and low or absent expression of CD24, as well as without displaying mammary 
lineage markers, such as CD2, CD3, CD10, CD16, CD18, CD31, CD64 and CD140b (Al-
Hajj et al., 2003). 
The CD44+ CD24-/low Lineage (Lin)- cells have a very elevated proliferative ability 
and were initially named as Cancer Initiating Cells, because just one hundred of these 
cells were able to engraft and grow as a tumor mass, when ten thousand of unselected 
cells failed. Even if they represent a very small portion of the tumor (11-35% of the Lin- 
cells), their number is sufficient to generate a neoplastic mass (Al-Hajj et al., 2003). 
Li and colleagues observed that this population is more present in HER2-positive 
breast cancers than in HER2-negative ones (10% versus 4.7%), suggesting a possible 
role of HER2 in sustaining the stemness of cancer cells. Moreover, the CD44+ CD24-/low 
Lin- cells showed drug resistance to chemotherapy (Li et al., 2008). In their study, 31 
patients with HER2-negative breast cancer were treated with docetaxel or doxorubicin 
and cyclophosphamide, whereas 21 patients with HER2-positive mammary carcinoma 
were treated with lapatinib, because previous studies had suggested a possible role of 
EGFR in maintaining the self-renewal ability in mammospheres (Farnie et al., 2007). 
Before and after the treatment, a biopsy from each patient has been collected and 
analyzed for the presence of CD44+ CD24-/low Lin- cells and for the ability of forming 
mammospheres in vitro. In HER2-negative breast cancer, both the percentage of BCSCs 
and the ability of forming mammospheres increased after the treatment with 
chemotherapy. On the contrary, a decrease in those parameters has been observed in 
HER2-positive biopsies after the treatment with lapatinib, even if not statistically 
significant (Li et al., 2008). 
HER2 has a fundamental role in BCSCs (Korkaya and Wicha, 2013). Ithimakin 
and colleagues observed that the CD44+ CD24-/low Lin- cells of bone metastases, 
originated from primary tumors classified as HER2-negative breast cancer, actually 
expressed HER2 with a mechanism that was not dependent on gene amplification. 
These cells expressed RANK, which binds to its ligand that is present in bone 
microenvironment and activated molecular pathways finally leading to HER2 
increased expression (Ithimakin et al., 2013). Moreover, HER2 expression in BCSCs is 
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also mediated by the interaction with several molecules, including CXCR1 and Notch 
(Korkaya and Wicha, 2013). 
HER2 expression might be important for the maintenance of the self-renewal 
ability, through the activation of the β-catenin signaling pathway and the inhibition of 
PTEN, which activates PI3K/Akt pathway (Korkaya et al., 2009). 
In mouse models of breast cancers, other stem cell markers have been identified, 
such as Sca-1, CD29, Thy1.1 and Nanog (Arigoni et al., 2013; Castagnoli et al., 2017). 
 
2.4 Anti-angiogenic therapies in mammary carcinoma 
Since the ten hallmarks of cancer include tumor angiogenesis, inhibiting the formation 
of new blood vessels inside the tumor is a possible therapeutic approach that can be 
considered in addition to targeted and conventional strategies. 
As previously said, it must be considered that tumor angiogenesis is not an 
efficient and homogeneous process. There can be hypoxic regions that enhance 
genomic instability, and hyperpermeability that interferes with the distribution of the 
drugs. Thus, normalizing the tumor vasculature may also be a valid strategy to 
improve therapeutic response: this approach is the so-called Jain’s concept (Goel et al., 
2011). 
Indeed, Willet and colleagues analyzed biopsies from rectal carcinoma patients 
treated with a single injection of bevacizumab, a monoclonal antibody that targets 
VEGF. They observed a reduction in tumor perfusion, in vascular volume, in the 
microvascular density, in interstitial fluid pressure and in the number of viable 
circulating endothelial and progenitor cells, whereas the fraction of vessels with 
pericyte coverage was increased (Willett et al., 2004).  
Since VEGF is the main molecular driver of physiological and pathological 
angiogenesis, it is logical that the major therapeutic strategies target VEGF itself (such 
as bevacizumab) or its receptors (like the inhibitors sunitinib and pazopanib) to inhibit 
its pathway. 
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2.4.1 Bevacizumab 
The first anti-angiogenic drug targeting VEGF was bevacizumab (Avastin®, Hoffmann-
La Roche), since it is well known that VEGF-A is upregulated in many tumor types, 
including breast cancer (Seddon et al., 2014). 
Bevacizumab binds all the major isoforms of VEGF with elevated affinity, 
preventing their binding to their receptor. Its effects include the reduction of vascular 
density, through the regression of existing vessels and the inhibition of the 
proliferation and migration of endothelial cells, which suppresses the development of 
new vessels. It also normalizes the aberrant characteristics of tumor angiogenesis and 
interacts with the immune system of the patient by increasing the levels of dendritic 
cells, T-lymphocytes and NK cells (Koutras et al., 2012). 
As it targets angiogenesis, the main adverse effects involve hypertension, 
proteinuria and hemorrhagic events. Less frequently, serious adverse events can be 
observed, such as arterial thromboembolism, wound healing complications, 
gastrointestinal perforation, reversible posterior leukoencephalopathy and congestive 
heart failure/cardiomyopathy (Koutras et al., 2012). 
In the metastatic setting, three phase III clinical trials showed an improvement in 
the progression-free survival (PFS) and in the objective response rate (ORR) with first-
line treatment with bevacizumab in association with chemotherapy, although no effect 
on overall survival (OS) was observed (Seddon et al., 2014; Trédan et al., 2015).  
The improvement in the PFS showed in the E2100 trial, where 722 patients with 
advanced breast cancer were randomized to receive bevacizumab plus paclitaxel or 
paclitaxel alone, led to the approval of bevacizumab by FDA for the treatment of 
HER2-negative metastatic breast cancer in 2008. Further trials failed to prove a 
significant improvement in OS. They rather showed an increase rate of grade 3-5 
adverse reactions (Seddon et al., 2014). 
Interestingly, Mikkael Sekeres, a physician at the Cleveland Clinic Taussig 
Cancer Institute and member of the Oncologic Drugs Advisory Committee to the FDA, 
wrote in a letter to the New England Journal of Medicine: «Well, I can offer you a drug 
that will not make you live longer, won’t make you feel better, and may have life-
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threatening side effects, but it will keep your cancer from worsening by an average of 
1-2 months» (Sekeres, 2011). 
Given the modest results in advanced breast cancer, the efficacy of bevacizumab 
was studied in patients with early stage mammary carcinoma, both in adjuvant and 
neoadjuvant settings. The use of bevacizumab might be beneficial in this context due to 
the role of VEGF in the initial phase of angiogenesis, that might be more important for 
carcinogenesis (Koutras et al., 2012). 
In HER2-negative early breast cancer in neoadjuvant regimen, a phase III trial 
showed just modest improvements in the PFS, in the pathological complete response 
(pCR) and in the ORR. However, the rate of adverse events increased, including 
cardiotoxicity when bevacizumab was administered in association with cardiotoxic 
drugs like anthracyclines (Seddon et al., 2014). 
Bevacizumab was also tested in patients with HER2-positive breast cancer, 
combination with trastuzumab. Like the previous studies, a small improvement in PFS 
and pCR was observed, as well as the adverse effect rate (Seddon et al., 2014). 
The approval of bevacizumab for the treatment of metastatic HER2-negative 
breast cancer was revoked in 2010 by FDA, as efficacy did not counterweight the risks. 
Nevertheless, EMA (European Medicine Agency) still supports its use in combination 
with paclitaxel (Koutras et al., 2012). 
Bevacizumab is also approved to treat on non-small cell lung cancer (NSCLC), 
renal cell cancer (RCC) and, as second-line treatment, glioblastoma (Kerbel, 2011). 
 
2.4.2 Sunitinib 
Sunitinib (Sutent®, Pfizer) is an oral small-molecule tyrosine kinase inhibitor (TKI) that 
targets several receptors including VEGFRs, PDGFRs, c-Kit, RET, CSF1R and Flt-3. 
Nowadays, it is approved for the treatment of renal cell cancer (RCC) and 
gastrointestinal stromal tumors (GIST). 
Several preclinical and clinical studies have investigated the efficacy of sunitinib 
in breast cancer. Although sunitinib was effective in preclinical xenograft models 
(Abrams et al., 2003), some clinical studies reported controversial results. A study 
reported a benefit as second-line treatment in monotherapy, especially in patients with 
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triple-negative or HER2-positive disease. However, another trial on HER2-negative 
breast cancer showed a worsening in terms of PFS in patients treated with sunitinib 
alone in comparison with patients treated with capecitabine. Other studies showed no 
improvement with the addition of sunitinib to chemotherapy (Koutras et al., 2012). 
Two recent clinical trials assessed the efficacy of sunitinib in combination with 
trastuzumab in patients with advanced HER2-positive breast cancer, showing some 
anti-tumor activity of the combined therapy. In one study, an objective response was 
observed in the 73% of the evaluable patients treated with sunitinib plus docetaxel and 
trastuzumab (Cardoso et al., 2012). In a following study, which involved a higher 
number of patients, the objective response rate was only 37%, but it was slightly higher 
in patients that did not receive any other treatment before (Bachelot et al., 2014). 
All phase I and II studies with safety as primary endpoint showed manageable 
adverse effects. These include fatigue, gastrointestinal disorders (diarrhea, nausea, 
stomatitis, dyspepsia and vomiting), hand-foot syndrome, skin discoloration and 
anorexia. The most severe adverse events include pulmonary embolism, 
thrombocytopenia, tumor hemorrhage, febrile neutropenia and hypertension (Nielsen 
et al., 2010). 
 
2.4.3 Pazopanib 
Pazopanib (Votrient®, GlaxoSmithKline) is another oral small-molecule TKI that blocks 
VEGFR2, PDGFRs and c-Kit, and has also modest activity against FGFRs (fibroblast 
growth factor receptors) and CSF1R (Schutz et al., 2011). It has been approved for the 
treatment of advanced or metastatic renal cell cancer and advanced soft-tissue 
sarcomas. 
The efficacy of pazopanib has been evaluated in breast cancer in some preclinical 
and clinical studies. One phase II trial studied the second- or third-line administration 
of pazopanib in HER2-negative recurrent or metastatic breast cancer, demonstrating 
little efficacy (Mackey et al., 2012). A recent phase II single-arm clinical trial studied the 
combination of pazopanib and paclitaxel after doxorubicin and cyclophosphamide as 
neoadjuvant therapy in HER2-negative locally advanced disease. A small pCR was 
observed, but the therapy was discontinued due to toxicity (Tan et al., 2015). 
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Another phase II study assessed the combination of pazopanib and lapatinib in 
metastatic HER2-positive mammary carcinoma as first-line therapy, showing a 
prolongation of the PFS (Mackey et al., 2012). The results on HER2-positive breast 
cancer seem promising, but still too few patients have been recruited so far. More 
investigations are needed to study the efficacy of this drug (Amiri-Kordestani et al., 
2012). 
Phase I clinical trials assessed the safety of pazopanib, demonstrating that it is a 
well-tolerated drug. The most relevant adverse events include nausea, fatigue, 
diarrhea, vomiting, rash, anorexia, visual disturbances, alopecia and constipation 
(Bossung and Harbeck, 2010).  
 
2.4.4 Resistance to anti-angiogenic therapies 
The controversial results obtained in several clinical studies question the convenience 
about using anti-angiogenic agents in breast cancer. 
VEGF is one of the main driver of angiogenesis, and targeting the VEGF-
dependent angiogenesis seems the most logical approach. However, there is the strong 
possibility that other alternative pathways are activated to sustain the formation of 
new blood vessels when VEGF is inhibited. Actually, the more the tumor is advanced, 
the more there are other proangiogenic factors that are upregulated in breast cancer, 
such as bFGF. This implies that the selective pressure set by the anti-angiogenic 
therapies may induce the selection of clones in which redundant pathways are active. 
In this way, the effect of anti-angiogenic drugs may be only transient (Kerbel, 2011). 
The subpopulations that anti-angiogenic therapy may select could be more 
aggressive, because the increasing hypoxia may upregulate HIF-α-related genes and 
thus promoting invasion, proliferation and metastatic dissemination. This can explain 
why only improvements in PFS, and not in OS, were observed in breast cancer (Kerbel, 
2011). 
Moreover, a preclinical study demonstrated that the therapy with anti-
angiogenic drugs causes the metabolic reprogramming towards aerobic glycolysis that 
leads to resistance to the treatment. Targeting the glycolytic enzymes restores the 
sensitivity (Wehland et al., 2013). 
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3. Preclinical mouse models of mammary carcinoma 
Transgenic models are animal models that express a homologous or xenogeneic gene 
that allows the establishment of a pathological condition. They are very useful to better 
understand the role of the transgene in causing the disease, to study its progression in 
a complex and alive organism, and to test novel therapeutic approaches (Wagner et al., 
1995). 
Starting from late ‘80s, several breast cancer transgenic models were developed. 
The first one was described by Muller and colleagues in 1988 and was transgenic for 
the activated form of rat c-neu on a FVB background (Muller et al., 1988). This model 
was followed by several other models, including one murine model that was 
transgenic for the rat proto-oncogene neu (Guy et al., 1992). Another model was 
transgenic for neuT (Lucchini et al., 1992), that was later brought on BALB/c 
background in the laboratory of Prof. Guido Forni and Prof. Federica Cavallo, in 
collaboration with the Laboratory of Immunology and Biology of Metastases (Boggio et 
al., 1998). 
 
3.1 FVBhuHER2 mice 
The first transgenic models for human HER2 did not develop autochthonous 
mammary carcinomas, but lung adenocarcinomas, Harderian gland tumors and B cell 
lymphomas (Suda et al., 1990). Another model had the transgene expression under the 
control of the promoter WAP (Whey Activating Protein), which guaranteed the 
expression of HER2 in the secretory mammary epithelium during pregnancy and 
lactation but not the development of breast cancer (Piechocki et al., 2003). 
The first human HER2-transgenic mouse model that developed mammary 
carcinomas was described by Finkle and colleagues in 2004. This model was called 
MMTV.f.huHER2 (but from now on it will be called FVBhuHER2). It was obtained by 
microinjecting a plasmid containing the cDNA of HER2 in an inbred FVB zygote. The 
transgene was put under the control of the promoter MMTV (Murine Mammary 
Tumor Virus), that is active in mammary epithelium by hormonal control. The 
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embryos that were obtained were implanted in a surrogate mother to generate a HER2-
transgenic lineage (Finkle et al., 2004). 
The female mice that were born were characterized from the molecular and 
phenotypic point of view. The transgene was successfully integrated into the genome 
in a single site on chromosome 6, and the copy number varied from 30 to 50. After 12 
weeks of age, the soluble form of HER2 was detectable, indicating the expression of the 
transgene in the normal mammary epithelium. This expression was confirmed by 
histological analysis. Moreover, the presence of HER2 was evaluated in other tissues: 
HER2 was also highly expressed in lungs, uterus, brain, skin, pancreas, adrenal glands, 
heart, esophagus and salivary glands (Finkle et al., 2004). 
The female mice were observed for 52 weeks. At the end of the follow-up, 73% of 
them had asynchronously developed mammary adenocarcinomas with an average 
latency of 36 weeks of age. Lung metastases were observed in 40% of the mice that 
developed tumors (Finkle et al., 2004). 
Somatic mutations were found in more than 80% of tumors. The majority was in 
the juxtamembrane region, whereas rare mutations were in the transmembrane region. 
About half of the mutations was in-frame. The other mutations, that were much less 
frequent, were insertions (4%), point mutations (18%) or combinations of deletions and 
point mutations (6%). The mutations described were not observed in normal mammary 
epithelium, and were more frequent in the exon 16 (Finkle et al., 2004). 
This model was also studied by at the Laboratory of Immunology and Biology of 
Metastases directed by Prof. Pier-Luigi Lollini at the Department of Experimental, 
Diagnostic and Specialty Medicine (DIMES), University of Bologna, Italy (De Giovanni 
et al., 2014; Castagnoli et al., 2014; Palladini et al., 2017). The median latency of this 
model was around 40 weeks, with the earliest tumors appeared around 30 weeks of 
age (Picture 8A). The follow-up was longer and Palladini and colleagues determined 
that tumor incidence could reach 100% after 75 weeks of age. These results reflect what 
observed by Finkle and his group. 
Tumor multiplicity, that is the mean number of tumor per mouse, was not very 
high in this model. Each FVBhuHER2 mouse developed an average of 1-2 tumors 
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(Picture 8B). The tumor growth was quite fast, reaching 1 cm3 after just 5 weeks after 
onset (picture 8C). 
Lung metastases were present in one bearing-tumor mice out of two, and the 
number of metastases was not high (picture 8D). The higher incidence of lung 
metastases compared to the one found by Finkle and colleagues can be explained by 
the longer follow-up of the observational experiment performed by the group at the 
Laboratory of Immunology and Biology of Metastases, that was well beyond 52 weeks. 
The appearance of the tumors was also analyzed. The tumors of FVBhuHER2 
female mice were typically reddish and hemorrhagic, with a soft and spongy texture 
(Balboni, MSc thesis; Palladini et al., 2017).  
 
3.2 Δ16-HER2 mice 
The first model that was transgenic for the splicing isoform Δ16 was described by 
Marchini and colleagues in 2011 (Marchini et al., 2011). It is the result of the 
collaboration between three Italian laboratories at the Istituto Nazionale dei Tumori in 
Milan, at the University of Camerino and at the University “G. D’Annunzio” of Chieti. 
Like FVBhuHER2 model, the transgene is placed under the control of the 
promoter MMTV. The plasmid that was used to transfect the FVB zygote also 
contained the gene of firefly luciferase, to let the visualization of the tumors by 
chemiluminescence. For this reason, this model was named Δ16-HER2-LUC, but from 
now on it will be simply called Δ16-HER2. 
The transgene resulted to be inserted in the genome in a unique site on 
chromosome 5, in an intergenic region lacking coding or regulatory sequences. The 
copy number is 5, and therefore much lower than in FVBhuHER2 model. 
Virgin female mice of the second generation were monitored by palpation. All 
the mice developed an average number of tumors of 4-5 with a mean latency of 15 
weeks. Earliest tumors appeared around the 12th week of age and all the mice were 
positive for the present of mammary carcinomas by 19 weeks of age. Lung metastases 
were detectable starting from the 25th week of age. 
The transgene was exclusively expressed in tumors, and no somatic mutations 
were detected. The authors proposed that these evidences may suggest that it is not 
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necessary a second mutational event for tumor onset, unlike in the FVBhuHER2 model 
(Marchini et al., 2011). 
Tumors were analyzed from the molecular point of view, revealing that Δ16 
stably homodimerized and the homodimers were constitutively active. Src was also 
active downstream, leading to the activation of STAT3. Other activated pathways 
involved Akt and MAPK (Marchini et al., 2011).  
This model was also studied at the Laboratory of Immunology and Biology of 
Metastases. The median latency and the mean tumor multiplicity observed were 
comparable to the ones observed by Marchini and colleagues (picture 8A and 8B; 
Castagnoli et al., 2014; Palladini et al., 2017). 
Tumor growth was slower that the one of FVBhuHER2. The volume reached 
after 5 weeks of follow-up was less than 0.5 cm3 (picture 8C). 
However, the metastatic burden to the lungs was similar, both regarding the 
number and the incidence of metastases (picture 8D). 
Macroscopically, Δ16-HER2 tumors looked very different than FVBhuHER2 
ones. They were usually pale and solid, with small hemorrhagic areas in rare cases 
(Balboni, MSc thesis; Palladini et al., 2017). These differences may suggest a possible 
role of the two isoforms in tumor angiogenesis. 
Another mouse model transgenic for Δ16 have been recently developed. 
Differently from Δ16-HER2 model, the expression of Δ16 is inducible in this model 
(Turpin et al., 2016). This model has been called ErbB2ΔEx16. Δ16 transgene was placed 
under the transcriptional control of the tetracycline response element. The FVB animals 
with these genomic features were crossed with a separate FVB strain expressing the 
reverse tetracycline transactivator under the transcriptional control of the MMTV 
promoter. The expression of the transgene was induced by adding doxycycline to the 
drinking water. The expression of Δ16 was restricted to the mammary and salivary 
epithelium. The tumors developed on this model showed an earlier onset than 
FVBhuHER2 mice: the first tumors appeared after 10 and 28 days after treatment with 
doxycycline in two different founder strains. Differently from HER2-expressing 
tumors, which have luminal-like features, ErbB2ΔEx16 tumors displayed 
characteristics that were more similar to basal-like tumors. Even in this model, Src 
Introduction 
51 
 
kinase was more activated than in FVBhuHER2 tumors. Moreover, Δ16 activated Stat3, 
Smad2 and HIF1α transcription factors. In addition, the metastatic burden to the lungs 
was higher than in FVBhuHER2 mice. They also proved that the stop of treatment with 
doxycycline was accompanied by tumor regression, but tumors reappeared after a 
variable tumor-free period. However, these recurrent tumors did not express Δ16 and 
displayed EMT features. 
 
3.3 FVBΔ16huHER2 (F1) mice 
Murine models that are transgenic for each HER2 isoform were developed, but a 
preclinical model that mimicked the clinical situation in which both full-length HER2 
and Δ16 are co-expressed was lacking. 
For this reason, the team of researchers at the Laboratory of Immunology and 
Biology of Metastases (University of Bologna, Italy) recently obtained a novel mouse 
model that is transgenic for both isoforms, created by crossing FVBhuHER2 and Δ16-
HER2 strains (Palladini et al., 2017). This model has been called F1 HER2/Delta16 (but 
in this thesis, it will be called simply F1). 
Double-transgenic female mice were monitored by palpation. The tumor-free 
survival curve overlapped the one of Δ16-HER2 mice, showing a median latency of 16 
weeks (picture 8A). On the other hand, tumor multiplicity was higher, with a mean 
number of tumors per mouse of 6-7 (picture 8B). Tumor growth rate was also similar to 
the one of Δ16-HER2 model (picture 8C), and so the incidence and number of lung 
metastases (picture 8D). 
These evidences suggest a dominant role of Δ16 in determining a faster 
carcinogenesis. However, HER2 and Δ16 seem to have a role only in the early stages of 
tumor onset and not in tumor progression, since there was no difference in metastatic 
spread between the three models. 
The appearance of F1 tumors seemed to be more heterogeneous. Both 
macroscopic characteristics of parental strains were observable, with a prevalence of 
pale and solid aspect, typical of Δ16-HER2 tumors (Balboni’s MSc thesis, 2014).  
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The level of expression of HER2 and Δ16 was evaluated in tumors and in 
preneoplastic mammary glands. Since no specific antibody for Δ16 is currently 
available, the expression of the two isoforms has been evaluated by Real Time qPCR. 
Both isoforms were expressed at intermediate levels in normal mammary tissue, 
compared to FVBhuHER2 and Δ16-HER2 tumors, but in F1 tumors the expression of 
the two isoforms were more heterogeneous. Most tumors expressed only Δ16 at high 
levels, whereas some tumors highly expressed both isoforms and only few had a high 
expression of the only full-length HER2 (picture 9). 
 
 
 
 
 
Picture 8. Comparison of spontaneous mammary carcinogenesis in FVBhuHER2 (black), Δ16-HER2 
(blue) and F1 (red) mice (Palladini et al., 2017). A: tumor-free survival. B: Tumor multiplicity. C: kinetics 
of tumor growth of the first tumor. C: number and incidence of lung metastases. 
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Picture 9. Expression of HER2 and Δ16 transcripts in F1 preneoplastic mammary glands and primary 
mammary carcinomas of FVBhuHER2 (black), Δ16-HER2 (blue) and F1 (red) mice (Palladini et al., 2017).  
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1. Mice 
FVBhuHER2 mice (Finkle et al., 2004) were obtained from Genentech Inc. (South San 
Francisco, CA, USA). This line carries in heterozygosis the human full-length HER2 
cDNA gene under the control of the Murine Mammary Tumor Virus (MMTV) 
promoter on a FVB background. HER2 gene heterozygosis was maintained by crossing 
FVBhuHER2 male mice with non-transgenic FVB female mice (purchased from Charles 
River Laboratories, Calco, Italy). 
Δ16-HER2 mice (Marchini et al., 2011) were kindly given by Prof. Augusto Amici 
(University of Camerino, Italy). This line carries in heterozygosis the human splice 
variant Δ16 cDNA gene under the control of MMTV promoter on a FVB background. 
Δ16 gene heterozygosis was maintained as described above for FVBhuHER2 model.  
F1 mice, transgenic for both genes, were obtained in the Laboratory of 
Immunology and Biology of Metastases directed by Prof. Pier-Luigi Lollini 
(Department of Experimental, Diagnostic and Specialty Medicine, University of 
Bologna, Italy) by crossing Δ16-HER2 male mice with FVBhuHER2 female mice. 
All the above-mentioned animals were bred in the animal facility of the 
Laboratory of Immunology and Biology of Metastases. Transgenic mice were screened 
by routine genotyping through PCR analysis (Finkle et al., 2004; Marchini et al., 2011). 
All the experiments on FVB, FVBhuHER2, Δ16-HER2 and F1 mice were 
approved by the institutional review board of the University of Bologna, authorized by 
the Italian Ministry of Health and done according to Italian and European guidelines. 
8-week-old female NOD-SCID mice were purchased from The Jackson 
Laboratories (Sacramento, CA, USA) and bred in the animal facility of the Instituto de 
Medicina Molecular (University of Lisbon, Portugal). The experiment performed on 
these mice was approved by the institutional review board of the Instituto de Medicina 
Molecular, authorized by the Portuguese National Authority for Animal Health 
(Direcção-Geral de Alimentação e Veterinária, DGAV) and done according to Portuguese 
and European guidelines. 
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2. Cell culture 
Four murine mammary tumor cell lines were employed in this project: MAMBO89, 
MAMBO38, MAMBO43 and Mi6. 
MAMBO89, MAMBO38 and MAMBO43 cell lines were obtained in the 
Laboratory of Immunology and Biology of Metastases. MAMBO89 cell line was 
established from a spontaneous mammary carcinoma of a FVBhuHER2 female mouse. 
MAMBO43 cell line was derived from a mammary carcinoma grown after the 
subcutaneous injection in a FVBhuHER2 female mouse of a FVBhuHER2 cell line 
established from a spontaneous FVBhuHER2 mammary carcinoma. MAMBO38 line 
was obtained and established in vitro from a tumor grown after the subcutaneous 
injection of MAMBO43. 
MAMBO89 and MAMBO43 cell lines were stabilized in Dulbecco’s Modified 
Eagle Medium (DMEM; Life Technologies, Milan) + 20% Fetal Calf Serum (FCS; Life 
Technologies, Milan, Italy), supplemented with Bovine Pituitary Extract 30 μg/ml (BPE; 
BD Biosciences, USA) and MITO Serum Extender 1:200 (BD Biosciences). MAMBO38 
was stabilized in DMEM + 20% FCS. 
Mi6 cell line was established from a spontaneous primary mammary carcinoma 
arisen in Δ16-HER2 model in the Laboratory of Dr. Elda Tagliabue and Dr. Serenella 
M. Pupa (Istituto Nazionale dei Tumori, Milan, Italy). Mi6 cell line was stabilized in 
MammoCult complete medium (StemCell Technologies, Canada) supplemented with 
1% FCS (Life Technologies, Milan, Italy). 
In the experiments reported in this thesis, MAMBO89 and Mi6 were cultured in 
MammoCult complete medium (StemCell Technologies, Canada) supplemented with 
1% FCS, whereas MAMBO43 and MAMBO38 were cultured in DMEM + 20% FCS, 
supplemented with BPE 30 μg/ml and MITO Serum Extender 1:200. 
Moreover, two humans breast cancer cell lines were employed: SKBr3 and MDA-
MB-231. SKBr3 was derived from the pleural effusion of a metastatic HER2-positive 
mammary adenocarcinoma and was kindly given to the Laboratory of Immunology 
and Biology of Metastases by Dr. Serenella M. Pupa (Istituto Nazionale dei Tumori, 
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Milan, Italy). MDA-MB-231 was purchased by ATCC and was derived from the pleural 
effusion of a metastatic triple-negative mammary adenocarcinoma. Both cell lines were 
cultured in Roswell Park Memorial Institute (RPMI; Life Technologies, Milan, Italy) + 
10% FCS (Life Technologies, Milan, Italy). 
MDA-MB-231 for the in vivo experiment was kindly given to the Vascular 
Morphogenesis Lab at the Instituto de Medicina Molecular (Lisbon, Portugal) by Dr. 
Sérgio De Almeida (Chromatin and Epigenetics Lab, Instituto de Medicina Molecular, 
Lisbon, Portugal) and cultured in DMEM + 10% FCS supplemented with 1% non-
essential amino acids (NEAA, Life Technologies). 
All mediums were supplemented with penicillin 100 U/ml and streptomycin 100 
µg/ml (Sigma-Aldrich, Milan, Italy). All cell lines were maintained at 37°C in a 
humidified 5% CO2 atmosphere. 
For the maintenance culture, cells were washed with Phosphate Buffer Saline 
(PBS; Life Technologies, Milan, Italy) and harvested by trypsin (0.05%)-EDTA (0.002%) 
treatment (Life Technologies, Milan, Italy). Cell number and viability were determined 
through erythrosine dye exclusion (Sigma-Aldrich, MO, USA) and cell count with a 
Neubauer chamber. 
 
2.1 FACS analysis 
FACS analysis was performed to evaluate the accumulation of doxorubicin and 
trastuzumab in tumor masses. After necropsy, tumors were minced with scissors, 
incubated for 5 minutes with trypsin-EDTA and passed through a 70 µm cell strainer 
(Becton Dickinson, Bedford, MA, USA) to obtain a homogeneous cell suspension.  
Tumors treated or not with doxorubicin were directly analyzed by flow 
cytometry considering that doxorubicin emits in the red spectrum. 
Tumors treated with trastuzumab were processed as described above as well. 
Before the incubation with the primary antibody, tumor suspensions were incubated 
with rat anti-mouse CD16/CD32 clone 2.4G2 antibody Fc block (1:100 dilution; BD 
PharMingen, San Diego, CA). Then, samples were incubated with the FITC-conjugated 
goat anti-human IgG secondary antibody (1:20 dilution; Invitrogen, CA, USA) or the 
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anti-human HER2 clone MGR2 primary antibody (1:100 dilution; Alexis Biochemical, 
Enzo Life Science, Lansen, Switzerland). Then, the samples incubated with MGR2 
antibody were incubated with the secondary fluorescein-conjugated mouse 
monoclonal antibody (IgG AlexaFluor 488, 1:100 dilution; Life Technologies, Milan, 
Italy). All samples were finally suspended in ethidium bromide 1 μg/ml (Sigma-
Aldrich, MO, USA) to stain dead cells. 
For the detection of BCSCs, cells were harvested and incubated with a mixture of 
two conjugated antibodies: anti-mCD24-AF (M1/69) (diluted 1:10; Bio-Legend, San 
Diego, CA, USA) and anti-mCD44-PE (IM7) (diluted 1:10; Bio-Legend, San Diego, CA, 
USA). 
Fluorescence intensity was determined through flow cytometry (Partec Cyflow 
Space, Sysmex). Analysis was performed with FCS Express 4 software (De Novo 
Software, Glendale, California, USA). 
 
2.2 Tube Formation Assay 
The Tube Formation Assay (Corning, NY, USA) consists in the seeding of cells on an 
appropriate scaffold made of Matrigel that allows the formation of vessel-like channels 
in vitro. 
Matrigel (Corning, NY, USA) was thawed on ice at 4°C overnight. The day after, 
it was diluted to 10 mg/ml in cold serum-free DMEM (Life Technologies, Milan, Italy). 
289 μl was added to a 24-well plate (Corning Life Sciences, USA) placed on ice, using 
pre-cooled tips and pipette. Plates were put at 37°C for 30-60 minutes to allow the 
Matrigel to solidify. 
Meanwhile, MAMBO89, MAMBO43, MAMBO38, Mi6, SKBr3 and MDA-MB-231 
cells were harvested and counted. 120,000 viable cells of each cell line were seeded in 
duplicate on Matrigel dropwise and incubated at 37°C in a humidified 5% CO2 
atmosphere. 
16-18 hours later, the vascular-like structures formed were counted under the 
inverted microscope Diavert (Leitz, Milan, Italy) with 2.5x magnification, dividing 
them according to their dimensions using a graded ocular. Tubes with a diameter 
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smaller than 0.5 mm were considered as “small”; tubes with a diameter of between 0.5 
and 1.5 mm were considered as “medium”; tubes with a diameter bigger than 1.5 mm 
were considered as “big”.  
Tubes were also photographed by using the Canon EOS600D camera (ISO200, 
exposition time 0.8 seconds). 
 
2.2.1 Impact of anti-angiogenic drugs on tube formation 
250,000 MDA-MB-231 viable cells and 500,000 MAMBO89 and Mi6 viable cells were 
seeded in 6-well plates (Corning Life Sciences, USA). The day after the seeding, the 
medium was replaced with: 
• fresh medium 
• DMSO 0.05% (Sigma-Aldrich, MO, USA) 
• sunitinib at a final concentration of 5 μM (LC Laboratories, MA, USA) 
• pazopanib at a final concentration of 5 μM (LC Laboratories, MA, USA) 
After 24 hours of treatment, cells were harvested, counted, resuspended in fresh 
drug-free medium and seeded on Matrigel 10 mg/ml, placed on 24-well plates 
(Corning Life Sciences, USA) as previously described. 120,000 cells of each cell line for 
each treatment were seeded in duplicate. 
18 hours later, the vascular-like tubes formed were counted dividing them by 
dimensions and photographed like described above. 
 
2.3 In vitro sensitivity to anti-angiogenic drugs 
250,000 MDA-MB-231 viable cells and 500,000 MAMBO89 and Mi6 viable cells were 
seeded in 6-well plates (Corning Life Sciences, USA). The day after the seeding, the 
medium was replaced with: 
• fresh medium 
• DMSO 0.05% (Sigma-Aldrich, MO, USA) 
• sunitinib at a final concentration of 5 μM (LC Laboratories, MA, USA) 
• pazopanib at a final concentration of 5 μM (LC Laboratories, MA, USA) 
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24, 48 and 72 hours after treatment, cells were harvested and counted to calculate 
the total number of cells per well and the percentage of growth over control. 
MAMBO38 was tested both in adherent conditions and in 3D-culture. For the 
experiment in adherent conditions, cells were seeded in a 96-well plate (Corning Life 
Sciences, USA) at a concentration of 1,000 viable cells per well. The day after, fresh 
medium containing or not DMSO 0.1%, sunitinib 5 μM or pazopanib 5 μM was added 
to each well. 
After 24 and 48 hours of treatment, WST-1 reagent (Sigma-Aldrich, MO, USA) 
was added to each well. WST-1 is a compound that is cleaved by mitochondrial 
dehydrogenases of viable cells into a compound that can be quantified by absorbance 
measurement. The absorbance was measured at 450 and 620 nm with an ELISA 
microreader (Tecan Systems) 60 minutes after the adding of WST-1 reagent. 
For the 3D-culture experiment, MAMBO38 cells were suspended in DMEM + 
20% FCS containing 0.33% agar (overlayer) and layered on a base of DMEM + 20% FCS 
containing 0.5% agar (underlayer) on a 24-well plate (Corning Life Sciences, USA) at a 
concentration of 1,000 cells per well. Drugs were added both to underlayer and to 
overlayer: 
• no drugs 
• DMSO 0.05% (Sigma-Aldrich, MO, USA) 
• sunitinib at a final concentration of 5 μM (LC Laboratories, MA, USA) 
• pazopanib at a final concentration of 5 μM (LC Laboratories, MA, USA) 
Plates were maintained at 37°C in a humidified 5% CO2 atmosphere. Colony 
growth was monitored weekly and determined by counting at 31.25x magnification 
with Diavert microscope (Leitz, Milan, Italy) after 2 weeks from seeding. Colonies were 
arbitrary defined as every cell aggregate bigger than 1 mm. The effectiveness of the 
drugs was assessed as percentage of colonies grown over control. 
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3. Preclinical models 
Virgin female mice were used in this thesis. Experimental animals were monitored 
weekly by palpation and tumor dimensions were measured with calipers. Masses with 
a mean diameter exceeding 3 mm were considered tumors. 
Mice were euthanized when tumor burden was equivalent to 10% of body mass. 
Tumor volume was calculated as (π/6) (√ab)3, where a = maximal tumor diameter and b 
= maximal tumor diameter perpendicular to a. 
At necropsy, tumor masses were collected for molecular and histological 
analyses.  
 
3.1 Histological analysis 
The histological analyses presented in this thesis have been performed in collaboration 
with Prof. Manuela Iezzi and Dr. Alessia Lamolinara from Aging Research Center, 
University “G. D’Annunzio” of Chieti, Italy. 
Autochthonous tumors from FVBhuHER2, Δ16-HER2 and F1 mice, and from F1 
MDI models were analyzed by immunofluorescence and by hematoxylin-eosin 
staining. Hematoxylin-eosin staining was performed on samples fixed in 10% neutral 
buffered formalin (Sigma-Aldrich, MO, USA) and embedded into paraffin. 5 μm slides 
were cut and stained with Hematoxylin (BioOptica, Milan, Italy) and Eosin (BioOptica, 
Milan, Italy) for histological examination. Immunofluorescence was performed on 
samples fixed in 4% PFA and frozen in a cryo-embedding medium (OCT, BioOptica, 
Milan, Italy). 4-6 μm cryostat sections were air-dried, fixed in ice-cold acetone for 10 
minutes and incubated with the following primary antibodies: rat monoclonal anti-
CD31 (550274, BD Pharmingen, BD Biosciences, San Jose, CA, USA) mixed with rat 
monoclonal anti-CD105 (550546, BD Pharmingen), and rabbit polyclonal anti-NG2 
(ab5320, EMD Millipore, Billerica, MA, USA), followed by secondary antibodies 
conjugated with Alexa 546 and Alexa 488 (Thermo Fisher Scientific), respectively. 
Nuclei were stained with DRAQ5 (Alexis, Life Technologies, Monza, Italy). The 
mixture of antibodies against CD31 and CD105 was used to increase the probability of 
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staining all the tumor endothelium. The same secondary antibody was used because 
there was not the need of distinguishing the presence and the quantity of each single 
protein on cell surface. 
Image acquisition was performed using Zeiss LSM 510 META confocal 
microscope. The number and area of vessels were evaluated on the digital images of 3-
5 tumors per group (five fields per tumor at 200x microscope) by two different 
pathologists, independently and in a blind fashion. Vessels area (in pixels) was 
evaluated with Adobe Photoshop by selecting vessels with the lasso tool and reporting 
the number of pixels indicated in the histogram window. 
FVBhuHER2 and Δ16-HER2 MDI tumors treated with vehicle or anti-angiogenic 
drugs were analyzed by immunohistochemistry. Tumors were fixed in 10% neutral 
buffered formalin (Sigma-Aldrich, MO, USA) and embedded into paraffin. 5 μm slides 
were cut. The samples were then deparaffinized, serially rehydrated and, after the 
appropriate antigen retrieval procedure, stained with anti-mouse CD31 (DIA-310, 
Dianova GmbH, Hamburg, Germany), followed by an appropriate anti-mouse 
secondary antibody (Jackson ImmunoResearch, West Grove, PA, USA). 
Immunoreactive antigens were detected using streptavidin peroxidase (Thermo Fisher 
Scientific, Waltham, MA, USA) and the Vulcan Fast Red Chromogen (Biocare Medical, 
Concord, CA, USA). After chromogen incubation, slides were counterstained in 
Hematoxylin (BioOptica) and images were acquired by Leica DMRD optical 
microscope (Leica, Wetzlar, Germany). The vascularization was analyzed by 
evaluating CD31-positive endothelial cells on digital images of 4-5 tumors per group, 
using Adobe Photoshop, by selecting vessels with the Magic Wand tool and reporting 
the number of pixels indicated in the histogram window with respect to the total area. 
Tumor necrosis was evaluated with Adobe Photoshop by selecting the necrosis area 
with the Lasso tool and reporting the number of pixels indicated in the histogram 
window as percentage of the total tumoral area. 
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3.2 Mouse-Derived Isografts 
Fragments of autochthonous F1 mammary tumors were serially implanted in the 
fourth left mammary fat pad of 5-17-week-old FVBhuHER2 transgenic female mice. 
Tumors grown from serial grafts of fragments from two F1 tumors (referred to as 
MoMo1 and MoMo2 respectively) were harvested for molecular investigation and also 
immediately implanted into other mice. 
Tumors from representative passages have been analyzed from the histological 
point of view as described before. In particular, passage I and IV of MoMo1, and 
passage III and V of MoMo2 have been examined. The number and the mean area of 
the vessels have been also quantified. 
 
3.3 Evaluation of doxorubicin and trastuzumab accumulation 
To evaluate drug delivery in tumors, a first experiment was performed exploiting the 
fluorescent properties of the chemotherapeutic drug doxorubicin. 7-15-week-old 
female FVB mice were subcutaneously injected with 5x106 viable MAMBO89 cells or 
with 5x106 viable Mi6 cells, cultured as described above. Tumor growth were 
monitored weekly and tumor dimensions were measured with a caliper.  
When tumors induced by the injection of MAMBO89 and Mi6 cells exceeded 1 
cm3, mice were divided into treated and untreated mice. Treated mice received an 
intravenous injection of doxorubicin (Accord, Milan, Italy) 16 mg/kg, diluted in PBS.  
Later the delivery of trastuzumab was examined. Three FVBhuHER2, bearing 
one tumor each, and two Δ16-HER2 mice, bearing one and two mammary carcinomas 
respectively, received an intraperitoneal injection of trastuzumab (Hoffmann-La Roche, 
Basel, Switzerland) 4 mg/kg, diluted in saline.  
In both experiments, mice were euthanized 2 hours after drug injection and 
tumors were collected to be dissociated mechanically and enzymatically. Tumor cell 
suspensions were then analyzed by flow cytometry.  
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3.4 In vivo sensitivity to anti-angiogenic and anti-HER2 drugs 
For the sensitivity to sunitinib and pazopanib according to HER2 and Δ16, fragments 
of five FVBhuHER2 or nine Δ16-HER2 autochthonous tumors were injected in 15 6-10-
week-old FVB female mice in the fourth left mammary fat pad. 
Tumor growth was monitored weekly for all the duration of the experiment. 
When tumors became palpable, mice were divided into three groups to receive 
sunitinib 60 mg/kg, pazopanib 100 mg/kg or the vehicle in which the drugs were 
dissolved (sterile methocel 0.5% + tween80 0.4% in tap water). Drugs were 
administered for four weeks, five days a week. 
For the combined therapy experiment, twenty-five tumor-free FVBhuHER2 
female mice were orthotopically injected in the fourth left mammary fat pad with 
fragments from six autochthonous mammary carcinomas of FVBhuHER2 mice to 
create a MDI model. Tumor growth was monitored weekly, and when the tumors 
became palpable, the animals were divided into five experimental groups: vehicle of 
sunitinib, sunitinib, trastuzumab, sunitinib and then trastuzumab, trastuzumab and 
then sunitinib. 
Sunitinib was administered at a dose of 60 mg/kg in methocel 0.5% + tween80 
0.4% in tap water for four weeks, five times a week. Trastuzumab was administered 
intraperitoneally at a dose of 4 mg/kg in saline, twice a week for four weeks. In the 
combined setting, four weeks of treatment with a drug were followed by four weeks of 
treatment with the other drug. 
In both experiments, mice were sacrificed one week after the end of the 
treatment. Necropsy was performed, and tumors were collected for molecular and 
histological analyses. 
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4. Gene expression analysis 
To explore the molecular differences between the tumor angiogenesis in FVBhuHER2, 
Δ16-HER2 and F1 models, gene expression analysis was performed on tumors. 
Spontaneous mammary carcinomas and MDI tumors have been collected and 
immediately frozen in liquid nitrogen to preserve RNA integrity. 
 
4.1 Real Time qPCR 
Frozen tissue samples were first disrupted by using the gentleMACS Octo Dissociator 
(Miltenyi Biotech GmbH, Bergisch Gladbach, Germany) with the program RNA_02. 
RNA was extracted according to the TRIzol protocol (Total RNA Isolation Reagent; 
Life Technologies, Milan, Italy). 
The concentration and purity of RNA was determined according to the protocol 
of the Qubit RNA Assay Kit (Life Technologies, Milan, Italy). 
1 µg of total RNA was reverse transcribed using iScript cDNA Synthesis Kit (Bio-
Rad Laboratories, CA, USA). The synthetized cDNA was diluted 1:4 with 
DNase/RNase free water. 
10 ng of cDNA was amplified by using Sso Advanced SyBR Green Supermix 
(Bio-Rad Laboratories, CA, USA) reagents. Gene expression was analyzed by Real 
Time qPCR using Thermal Cycler CFX96 (Bio-Rad Laboratories, CA, USA). 
 Evaluated target genes were: human HER2 and Δ16, and mouse KDR, FGF2, 
MCAM, PECAM1, PTGS2 and VEGF-A. mRNA expression levels were normalized to 
mouse GAPDH (glyceraldehyde 3-phosphate dehydrogenase) or mouse TBP (TATA 
box binding protein), as endogenous reference genes.  
HER2, Δ16, GAPDH and TBP primers were purchased from Life Technologies 
(table III for primer sequences) and were used at a final concentration of 200 nM. KDR, 
FGF2, MCAM, PECAM1, PTGS2 and VEGF-A primers were purchased from Bio-Rad 
Laboratories and were used at a final dilution of 1X (table IV for primer references). 
The steps of amplification for GAPDH were: 95°C for 30 seconds and then 40 
cycles including 5 seconds at 95°C and 15 seconds at 60°C. For HER2, Δ16 and TBP, the 
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steps of amplification were: 95°C for 30 seconds and then 40 cycles including 5 seconds 
at 95°C and 15 seconds at 65°C. The steps of amplification for angiogenesis-related 
genes were: 95°C for 30 seconds and then 40 cycles including 5 seconds at 95°C and 30 
seconds at 60°C. A default melting curve program was used to obtain the dissociation 
curve for each gene. 
The analysis was performed using Bio-Rad CFX Manager 3.1 software. For 
relative quantification, Ct method was used:  
Ct gene= Ct gene – Ct housekeeping 
 
Gene Sequence (5’- 3’) 
Full-length human HER2  
(Mitra et al., 2009) 
For: GTGTGGACCTGGATGACAAGGG 
Rev: GCTCCACCAGCTCCGTTTCCTG 
Human ∆16 
(Mitra et al., 2009) 
For: CACCCACTCCCCTCTGAC 
Rev: GCTCCACCAGCTCCGTTTCCTG 
Mouse GAPDH 
For: GCTCACTGGCATGGCCTTC 
Rev: CCTTCTTGATGTCATCATACTTGGC 
Mouse TBP 
(Bieche et al., 2014) 
For: CCCTTGTACCCTTCACCAATGAC 
Rev: TCACGGTAGATACAATATTTTGAAGCTG 
Table III: primer sequences from Life Technologies, Milan, Italy. 
 
Gene Reference 
FGF2 (b-FGF) qMmuCED0049098 
KDR (VEGFR2) qMmuCID0005890 
PECAM1 (CD31) qMmuCID0005317 
MCAM (CD146) qMmuCID0023780 
PTGS2 (COX-2) qMmuCED0047314 
VEGF-A qMmuCED0040260 
Table IV: primer references from Bio-Rad Laboratories, CA, USA. 
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4.2 PCR Array 
RNA has been extracted, purified and quantified from four FVBhuHER2 mammary 
tumors and four Δ16-HER2 ones following the protocol of the Aurum Total Fatty and 
Fibrous Tissue Kit (Bio-Rad Laboratories, CA, USA). 
After mRNA quantification and cDNA synthesis as described above, PrimePCR 
Angiogenesis (SAB target list) Array was used (Bio-Rad Laboratories, CA, USA). This 
PCR Array analyzes the expression of 82 genes involved in angiogenesis by Real Time 
qPCR. It consists of a 96-well qPCR plate which includes different specific primers in 
each well. Therefore, each sample was plated into one PCR Array plate and Real Time 
qPCR has been performed using Sso Advanced SyBR Green Supermix. 
ΔCt was calculated as described before, using as reference the six housekeeping 
genes included in the PCR Array (actin-β, B2M, GUSB, TBP, HPRT1 and GAPDH). The 
analysis of the results has been performed to identify all the genes that were up- or 
down-regulated in FVBhuHER2 tumors in comparison to Δ16-HER2 ones, considering 
all those genes with a higher fold change than 4, calculated using Bio-Rad CFX 
Manager 3.1 software. 
 
 
5. Protein analysis 
5.1 Tumor lysis and quantification of proteins 
Frozen tumor tissues of two FVBhuHER2 tumors and two Δ16-HER2 ones were 
completely immersed in lysis buffer consisting of Novagen PhosphoSafe Extraction 
Reagent (EMD Millipore, MA, USA) plus phosphatase and protease inhibitors (Sigma-
Aldrich, MO, USA). 
Samples were dissociated and homogenized by gentleMACS Octo Dissociator 
(Miltenyi Biotech GmbH, Bergisch Gladbach, Germany) and then incubated for 10 
minutes at room temperature. Nuclei were removed by centrifugation at 12,000 RCF at 
4°C for 15 minutes, and protein concentration in the supernatants was determined by 
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DC Protein Assay (Bio-Rad Laboratories, CA, USA) using bovine serum albumin as 
standard. 
 
5.2 Antibody Array 
The Proteome Profiler Mouse Angiogenesis Array Kit (R&D Systems Inc, MN, USA) is 
an Antibody Array that consists in the analysis of the amount of 53 specific proteins 
involved in angiogenesis by using a membrane on which a collection of capture 
antibodies is spotted in duplicate. 
Two FVBhuHER2 tumors and two Δ16-HER2 ones were compared with 
Antibody Array analysis. To be sure that the samples were homogenous between each 
other, a Western Blot for actin was previously performed. 
For each sample, 200 μg of tumor lysate were mixed with a cocktail of 
biotinylated detection antibodies. These mixtures were added on the membrane to 
allow the binding of the proteins to the capture antibodies. Streptavidin-horseradish 
peroxidase and detection reagents were added to produce a chemiluminescent signal 
where the proteins were captured by the antibodies, with an intensity that is 
proportional to its amount in the lysate. This system of chemiluminescent detection of 
protein presence is therefore similar to a Western blot. 
Protein presence was therefore revealed by chemiluminescence reaction and 
images of the membranes were taken using the ChemiDoc Imaging System (Bio-Rad 
Laboratories, CA, USA) at the Laboratory of Prof. Gabriella Campadelli-Fiume of the 
University of Bologna. An exposition time of 630 seconds was used for all membranes. 
The calculation of spot volume was performed on the scanned images by using 
TotalLab gel analysis software (TotalLab Ltd, UK). Percent fold change of FVBhuHER2 
proteins compared to Δ16-HER2 ones was calculated as follows: 
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The mean of results of FVBhuHER2 and Δ16-HER2 tumors analyses was 
calculated. The differences in protein presence between FVBhuHER2 tumors and Δ16-
HER2 ones with a percent fold change higher than 25 and/or with a p value less than 
0.05 were considered. 
 
 
6. Statistical analysis 
Student’s t test was used to analyze and compare the data presented in this thesis. The 
comparisons were considered statistically different with a p value less than 0.05. 
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1. HER2 and vascular phenotype 
The proto-oncogene HER2 is over-expressed in 15-20% of human breast cancers. In 
about half of them a splicing isoform lacking exon 16, and therefore called Δ16, is 
present as well. 
Preclinical models that are transgenic for full-length HER2 and/or Δ16 have been 
developed. These mouse models are characterized by the spontaneous development of 
multiple mammary carcinomas in female mice. Carcinogenesis occurs earlier in Δ16-
HER2 and in double-transgenic (F1) mice than in FVBhuHER2 mice (Castagnoli et al., 
2014; Palladini et al., 2017). F1 tumors could express at high levels both isoforms or 
only one (Palladini et al., 2017). 
The autochthonous tumors developed on FVBhuHER2, Δ16-HER2 and F1 mice 
were macroscopically different. The mammary tumors of FVBhuHER2 mice were often 
hemorrhagic, reddish and spongy. Tumors of Δ16-HER2 mice were typically whitish 
and had a solid texture, with rare and small hemorrhagic areas in some cases. The 
appearance of F1 tumors was more heterogeneous, with a prevalence of Δ16-HER2-like 
phenotype (Balboni’s MSc thesis, 2014; Palladini et al., 2017). 
To investigate whether the differences observed did not only concern the 
macroscopic appearance, tumors from the three mouse models were collected to be 
analyzed from the histological and molecular point of view. 
The effect of modulation of HER2 expression on vascularization was also 
explored through an in vivo model that is characterized by the stable expression of Δ16 
and by the fluctuation of the levels of HER2 expression. 
Lastly, the vasculogenic ability of HER2- and/or Δ16-expressing tumor cells was 
studied in vitro, following the protocol of the Tube Formation Assay. 
 
1.1 HER2 isoforms and vascular architecture of mammary tumors 
The tumors of FVBhHER2, Δ16-HER2 and F1 mice were not only different in the 
macroscopic appearance, but they also differed microscopically. The histological 
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analysis of the tumors has been performed in the laboratory of Prof. Manuela Iezzi of 
the Aging Research Center, “Gabriele D’Annunzio” University, Chieti, Italy. 
Hematoxylin-eosin staining evidenced the presence of few large vessels or 
vascular lacunae in tumors of FVBhuHER2 (figure 1A). On the other hand, Δ16-HER2 
carcinomas were characterized by numerous small endothelium-lined vessels (figure 
1B). In F1 tumors both phenotypes could be found (figure 1C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To better characterize the vascular architecture and the composition of blood 
vessels, immunostaining of endothelial cells and pericytes has been performed. 
Endothelium has been labeled by using anti-CD31 and anti-CD105 antibodies. An anti-
NG2 antibody was used to label pericytes (figure 2).  
 
 
A B 
C 
Figure 1. Different vascular patterns in transgenic mammary carcinomas of FVBhuHER2 (A), Δ16-HER2 
(B) and F1 (C) mice. Hematoxylin-eosin staining are shown, with a 100x magnification (Palladini et al., 
2017). 
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As it was observable in hematoxylin-eosin stained samples, FVBhuHER2 tumors 
were characterized by few large vessels (figure 2A). On the contrary, the vascular 
phenotype of Δ16-HER2 was characterized by many small vessels (figure 2B).  
To investigate the role of the two isoforms in determining the vascular pattern, 
F1 tumors have been examined considering that HER2 and Δ16 can be co-expressed or 
only one isoform can be highly expressed. Tumors that expressed both isoforms (figure 
2C) or that expressed only full-length HER2 at high levels (figure 2D) showed a 
vascular pattern similar to the one typical of FVBhuHER2 mice, with few large vessels. 
On the other hand, F1 tumors with high expression of Δ16 and a low expression of 
HER2 (figure 2E) showed many small vessels, as it is characteristic of Δ16-HER2 
tumors. 
The quantification of the mean area and the number of vessels has been 
performed (figure 3). The analysis confirmed that the vessels of FVBhuHER2 tumors 
Figure 2.  Vascular phenotype of FVBhuHER2 (A), Δ16-HER2 (B) and F1 (C-D-E) tumors. F1 tumors have 
been divided according to the levels of expression of HER2 and Δ16. Primary anti-CD31 and anti-CD105 
antibodies have been used to stain endothelium (in red). Primary anti-NG2 antibody has been used to 
label pericytes (in green). Images obtained using a confocal microscope. Magnification: 200x. 
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are statistically fewer than the vessels of Δ16-HER2 tumors, but their mean area is 
bigger. 
Analyzing the characteristics of the vessels among the F1 tumors according to 
their relative expression of HER2 and Δ16, it was confirmed that F1 HER2high Δ16low and 
F1 HER2high Δ16high have larger and fewer vessels than F1 HER2low Δ16high tumors, 
therefore resembling the features of FVBhuHER2 and Δ16-HER2 tumor respectively. 
Thus, it is possible to conclude that when full-length HER2 is expressed at high 
levels, regardless of the level of expression of Δ16, the vessels are larger and fewer. 
When only Δ16 is highly expressed, the vessels are smaller and more numerous. In this 
sense, the full-length form of HER2 seems to have a dominant role in determining 
tumor vascularization in comparison to Δ16.  
 
 
 
 
 
 
 
 
 
 
1.2 Modulation of HER2 and vascular phenotype 
To better understand the role of HER2 and its splice isoform Δ16 in regulating tumor 
vascularization, the vascular pattern has been analyzed using an in vivo model of 
modulation of the expression of full-length HER2. 
This model has been obtained through serial in vivo transplants of two F1 tumors 
in syngeneic immunocompetent mice. These mouse-derived isograft (MDI) models 
have been called MoMo1 and MoMo2. 
B A 
Figure 3.  Quantification of the vascular area (A) and number (B) of vessels per high power field (HPF) 
×200, in FVBhuHER2 (in black), Δ16-HER2 (in blue) and F1 (in red) tumors. Each bar represents the mean 
and SEM of five×200 fields for each tumor (n=3-5). Statistical analysis (Student's t test): *=p<0.05, **=p<0.01. 
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The tumors of these models have been analyzed by Real Time qPCR to determine 
the kinetics of expression of full-length HER2 and Δ16. In particular, MoMo1 was 
characterized by a high expression of both isoforms at the first two passages, and then 
the expression of full-length HER2 decreased. The expression of Δ16 remained stable 
over serial passages (figure 4A). MoMo2, on the contrary, showed a high expression of 
Δ16 and a low expression of HER2 at the beginning, and later the levels of the full-
length form progressively increased (figure 4B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Kinetics of expression of HER2 isoforms and of the vascular phenotype during serial passages 
of F1 tumors (MDIs). A-C-E: model MoMo1. B-D-F: model MoMo2. A-B: Expression of full-length HER2 
(white rounds) and Δ16 (black triangles) obtained by Real Time qPCR. Housekeeping gene: mTBP. C-D 
and E-F: respectively area and number of the vessels of the tumors of two different in vivo passages of 
MoMo1 and MoMo2 models, measured by CD31 immunostaining; each bar represents the mean and the 
SEM of four×200 fields for each tumor (n=3-5). Statistical analysis (Student’s t test): **=p<0.01; ***=p<0.001. 
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Similarly to what done for autochthonous mammary carcinomas, the tumors of 
different passages from both MDIs have been analyzed. The passages were chosen to 
represent different points of the kinetics of HER2 expression. 
In MoMo1 models, high levels of full-length HER2 observed at the first passage 
was associated with a vascular pattern with few large vessels, as well as FVBhuHER2 
tumors. The subsequent loss of HER2 expression observed at the fourth passage, was 
accompanied by the acquisition of the Δ16-HER2-like phenotype, with an increased 
number of smaller vessels (figure 4C and 4E). 
In model MoMo2, that had a specular kinetics of expression of full-length HER2 
in comparison with MoMo1, an opposite trend was observed: at the third passage, 
when only Δ16 was expressed at high levels, the tumors had many small vessels, but at 
the fifth passage the higher HER2 levels caused the increase of the mean area of the 
vessels (figure 4D) and the decrease of their number (figure 4F). 
These results confirmed the dominant role of HER2 in affecting tumor 
vasculature, even in dynamic models such as the MDIs that have been developed. 
Moreover, the direct responsibility of HER2 on vascularization has been confirmed. 
 
1.3 Expression of angiogenesis-related genes 
In order to study the molecular profile associated with the different vascular patterns 
and the expression of full-length HER2 and Δ16, the autochthonous mammary tumors 
developed on FVBhuHER2, Δ16-HER2 and F1 mice have been analyzed from the 
molecular point of view. As done before, F1 tumors have been divided into three 
subgroups according to their levels of expression of HER2 and Δ16. 
As a preliminary test, six angiogenesis-related markers have been taken into 
consideration (figure 5): VEGFR2 (KDR), FGF2 (bFGF), MCAM (CD146), PECAM1 
(CD31), PTGS2 (COX-2) and VEGF-A. 
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Figure 5. Expression of angiogenesis-related genes by Real Time qPCR in FVBhuHER2 (black bars), Δ16-
HER2 (blue bars) and F1 (red bars) tumors. A: KDR (VEGFR2). B: FGF2 (bFGF). C: MCAM (CD146). D: 
PECAM1 (CD31). E: PTGS2 (COX-2). F: VEGF-A. Each bar represents the mean and the SEM of ΔCt for 
each tumor (n=3-19). Housekeeping gene: mGAPDH. Statistical analysis (Student’s t test): *=p<0.05; 
**=p<0.01. Borderline statistical comparisons (PTGS2): Δ16 vs. F1 HER2highΔ16low p=0.090; F1 
HER2highΔ16low vs. F1 HER2lowΔ16high p=0.091. 
A 
B 
C D 
E F 
Results 
82 
 
The expression of VEGFR2 was lower in FVBhuHER2 tumors than in Δ16-HER2 
ones. Among F1 tumors, those which highly express HER2 showed a lower expression 
of VEGFR2 than F1 HER2low Δ16high tumors. The presence of high levels of Δ16 did not 
seem to influence the expression of VEGFR2, since the bar corresponding to the F1 
tumors that co-express the two isoforms is the lowest one (figure 5A). 
In general, FGF2 was poorly expressed by all tumors. Moreover, no statistical 
difference in expression was detected among the different tumors (figure 5B). 
MCAM and PECAM1, which are endothelial markers, were more expressed than 
FGF2 but no difference was found between the levels of expression of the five 
subgroups of tumors (figure 5C and 5D respectively). 
On the contrary, COX-2 expression showed some differences that seem to be 
negatively correlated with the high expression of Δ16. In particular, Δ16-HER2 tumors 
showed a higher expression of COX-2 than FVBhuHER2 ones. Among F1 subgroups, in 
F1 HER2high Δ16high and F1 HER2low Δ16high tumors the expression of COX-2 is lower 
than in F1 HER2high Δ16low (figure 5E). 
VEGF-A is highly expressed by all tumors, but some statistical differences have 
been detected. The expression of this gene is the highest in Δ16-HER2 tumors, where 
the expression of HER2 is completely absent. F1 tumors, regardless of the expression of 
the two isoforms, showed a level of expression comparable to the one of FVBhuHER2 
tumors. In this sense, even low levels of HER2 seem to be sufficient to keep lower the 
expression of VEGF-A (figure 5F). 
The analysis of the molecular differences between the vascular patterns sustained 
by HER2 and its isoform Δ16 has been extended to a higher number of angiogenesis-
related markers using tools such as PCR arrays and antibody arrays. 
The first technique analyzes the gene expression by Real Time qPCR. It consists 
of a qPCR plate which contains specific different primers in each well.  
Ten genes were found to be more expressed in FVBhuHER2 tumors, three of 
which reached the statistical significance (i.e. Angiopoietin-1, Csf3 and CXCL5; figure 
6A). On the other hand, four genes were more expressed in Δ16-HER2 tumors, but only 
Leptin reached the statistical significance (figure 6B). 
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Figure 6. Expression of angiogenesis-related genes in FVBhuHER2 (black bars) and Δ16-HER2 (blue bars) 
tumors. A and B: up- and down-regulated genes in FVBhuHER2 tumors compared to Δ16-HER2 ones, 
respectively (cut-off: fold change > 4) obtained by PCR array. Each bar represents the mean and the SEM 
of the ΔCt of each tumor (n=4 for each group), obtained subtracting the mean Ct of a collection of six 
housekeeping genes to the Ct of each tumor. C: amount of angiogenesis-related proteins obtained by 
antibody array (cut-off: fold change > 25 and/or statistical significance reached). Each bar represents the 
mean and the SEM of the volumes of the two spots for each protein (n=2 for each group). Statistical 
analysis (Student’s t test): *=p<0.05; **=p<0.01; ***=p<0.001. 
C 
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The second approach consists in the analysis of the amount of specific proteins 
using a membrane on which a collection of capture antibodies is spotted in duplicate.  
Twenty-three proteins were identified with a fold change higher than 25 and/or a 
statistically significant difference between FVBhuHER2 and Δ16-HER2 tumors. Eleven 
proteins were statistically different between the two groups of tumors: delta-like ligand 
4 (Dll-4), Endoglin, Endostatin, HB-EGF, IGFBP-3, MMP-9, Osteopontin, PDGF-AB/BB, 
stromal cell-derived factor 1 (SDF-1), Serpine E1 and TIMP-1 (figure 6C). 
Comparing the results obtained from these two techniques, three markers were 
in common: Angiopoietin-1, EGF and TIMP-1. These might be good candidate genes to 
further explore the differences in vascularization driven by the two isoforms. 
 
1.4 Distribution of drugs 
The different patterns of vascularization induced by the two isoforms were analyzed 
from the functional point of view, in order to explore whether there was a difference in 
the delivery of therapeutic agents into the tumor mass. 
A first approach consisted in the cytofluorimetric analysis of the accumulation of 
doxorubicin in tumors. Doxorubicin is a chemotherapeutic drug with fluorescent 
properties that can be detected and measured by flow cytometry. 
The two cell lines MAMBO89 and Mi6, derived from an FVBhuHER2 mammary 
carcinoma and a Δ16-HER2 tumor respectively, were injected subcutaneously in non-
transgenic FVB female mice. When the tumors reached a volume higher than 1 cm3, 
that was 8 and 5 weeks after injection respectively, the mice were divided into control 
and treated group, and doxorubicin 16 mg/kg was injected intravenously in the latter. 
All the mice were euthanized two hours after the treatment and the tumors were 
collected to obtain cell suspension to be analyzed by flow cytometry. 
The analysis of the results has been performed by calculating the fluorescence 
ratio between the medians of intensity of treated and untreated mice. Δ16-expressing 
tumors significantly accumulated more doxorubicin than HER2-espressing ones (figure 
7A), thus indicating that the different vasculatures sustained by HER2 and Δ16 have a 
functional impact on drug delivery. 
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To validate these results, we also evaluated the delivery of the HER2-targeted 
drug trastuzumab. Since it is a humanized antibody, an anti-human IgG antibody was 
used to measure the amount of the drug inside the tumors by flow cytometry. 
Three FVBhuHER2 mice, bearing one mammary tumor each, and two Δ16-HER2 
mice, bearing one and two tumors respectively, were injected with trastuzumab 4 
mg/kg intraperitoneally. Like the experiment with doxorubicin, mice were sacrificed 
after two hours to collect the tumors, and tumor suspensions were analyzed by flow 
cytometry. The median of fluorescence intensity of each tumor was normalized on the 
expression of total HER2. 
The results obtained with this approach confirmed the outcome of the previous 
experiment: Δ16-HER2 tumors accumulated more trastuzumab than FVBhuHER2 ones, 
even if statistical significance was not reached (figure 7B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Doxorubicin accumulation 
Figure 7. Drug accumulation in FVBhuHER2 (black bars) and Δ16-HER2 (blue bars) tumors detected by 
flow cytometry. A: accumulation of doxorubicin expressed as fluorescence ratio between the median of 
fluorescence intensity of tumors of treated and untreated mice. Each bar represents the mean and SEM of 
5-6 tumors. B: accumulation of trastuzumab expressed as fluorescence intensity normalized on HER2 
expression of each tumor. Each bar represents the mean and the SEM of 3 tumors. Statistical analysis 
(Student’s t test): **=p<0.01. 
A B 
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1.5 In vitro evaluation of tube formation ability of tumor cells 
Vascular mimicry (VM) is a type of angiogenic mechanism that consists in the 
participation of tumor cells in vascular architecture. Tumor cells with stem cell-like 
features can undergo an epithelial-mesenchymal transition (EMT) that confers an 
endothelial-like phenotype. VM was found to be present in HER2-positive (Liu et al., 
2013) and in triple-negative breast cancers (Plantamura et al., 2014). 
VM activity can be detected by using an in vitro test that consists in the seeding of 
tumor cells on Matrigel to test their attitude to form vessel-like structures. This test is 
called Tube Formation Assay (Maniotis et al., 1999).  
To study the capability of forming lacunae in vitro conferred by full-length HER2 
and Δ16, different human and murine breast cancer cell lines have been used, selected 
for their different characteristics in terms of expression of the two isoforms.  
Four murine cell lines were taken into account: three derived from tumors of 
FVBhuHER2 mice (MAMBO89, MAMBO43 and MAMBO38) and one derived from a 
tumor of a Δ16-HER2 mouse (Mi6). 
The cell line MAMBO89 has a high and stable expression of full-length HER2, 
whereas the cell line MAMBO43 has a high expression of HER2, but that is lost after 
the treatment with drugs or in vivo injection. 
The cell line MAMBO38 was derived from a tumor induced by the in vivo 
injection of MAMBO43. It is characterized by the loss of HER2 expression and it 
underwent an epithelial-mesenchymal transition (EMT). 
Moreover, two human breast cancer cell lines were considered: MDA-MB-231 
(which does not express HER2 because it derives from a triple-negative breast cancer, 
and it is known to form vessel-like structures on Matrigel) and SKBr3 (which expresses 
both HER2 and Δ16 and it is known to be unable to form tubes). Therefore, these cell 
lines were used as positive and negative control respectively (Plantamura et al., 2014). 
Tubes that have formed after 16 hours from the seeding have been divided 
according to their dimensions, using a graded ocular (table 1). Tubes with a diameter 
smaller than 0.5 mm were considered as “small”; tubes with a diameter of between 0.5 
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and 1.5 mm were considered as “medium”; tubes with a diameter bigger than 1.5 mm 
were considered as “big”. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The two cell lines that express neither HER2 nor Δ16 (MAMBO38 and MDA-MB-
231, figure 8C and 8E respectively) showed an elevated ability of forming tubes in vitro. 
Cells placed to form a reticle throughout the well, and they were the only cell lines that 
were also able to form big tubes. In particular, MAMBO38 was the one that formed 
F E 
D C 
A B 
Figure 8. Tube Formation Assay in vitro of MAMBO89 (A), MAMBO43 (B), MAMBO38 (C), Mi6 (D), 
MDA-MB-231 (E) and SKBr3 (F) cell lines. Pictures taken under an inverted microscope with a 2.5x 
magnification (0.8” of exposure, ISO 200). Red arrow: big tube. Green arrow: medium tube. Blue arrow: 
small tube. 
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most tubes, with a mean number of tubes formed of 115 (p<0.05 vs. MDA-MB-231, 
p<0.01 or p<0.001 vs. the other cell lines by the Student’s t test). 
The cell lines that express only full-length HER2 (MAMBO89 and MAMBO43, 
figure 8A and 8B respectively) have a limited but present capability of forming vessel-
like structures, even of medium dimensions.  
As expected, SKBr3 cell line did not form any tubes (figure 8F). Interestingly, the 
other cell line that expresses Δ16, that is Mi6 (figure 8D), do not seem to be able to form 
tubes in vitro, too. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.6 Detection of Breast Cancer Stem Cells 
The  presence of Breast Cancer Stem Cells (BCSCs) defined as CD44+ CD24-/low cells 
have been evaluated in representative cell lines of FVBhuHER2 and Δ16-HER2 tumors 
by flow cytometry. Anti-CD44 and anti-CD24 antibodies have been used to evaluate 
the presence of this specific population of BCSCs in MAMBO89, Mi6 and MAMBO38 
cell lines (figure 9). 
 
Cell lines Small tubes 
Medium 
tubes 
Big tubes Total Mean 
MAMBO89 
11 0 0 11 
12 
11 1 0 12 
MAMBO43 
4 0 0 4 
5 
3 2 0 5 
MAMBO38 
79 27 10 116 
115 
92 14 8 114 
Mi6 
0 0 0 0 
1 
1 0 0 1 
MDA-MB-231 
41 7 8 56 
66 
50 18 8 76 
SKBr3 
0 0 0 0 
0 
0 0 0 0 
Table 1. Number of vessel-like structures (tube) in murine and human breast cancer cell lines by Tube 
Formation Assay in vitro. Small tubes: diameter smaller than 0.5 mm; medium tubes: diameter of 
between 0.5 and 1.5 mm; big tubes: diameter bigger than 1.5 mm. 
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The population of CD44+ CD24-/low cells was present in MAMBO89 cell line, 
representing the 18% of the total population (figure 9A). In Mi6 cells, CD44+ CD24-/low 
cells have not been detected (figure 9B). Interestingly, in MAMBO38 this population 
represented almost the totality of the total cell population (figure 9C). 
 
 
2. Angiogenesis and sensitivity to anti-tumoral 
drugs in HER2-positive mammary carcinoma 
As it was shown before, the different vascular patterns sustained by HER2 and Δ16 
affect the distribution of drugs. This fact may influence the sensitivity to anti-tumoral 
drugs such as trastuzumab. 
The different vascularization may also affect the sensitivity to anti-angiogenic 
drugs, such as sunitinib and pazopanib. Moreover, according to the Jain’s concept 
(Goel et al., 2011), drugs that target angiogenesis may have a direct effect on the 
vascular phenotype of tumors, thus potentially affecting the sensitivity of other 
therapeutic agents. 
The sensitivity to anti-angiogenic agents has been first explored in vivo, in 
monotherapy or in association with trastuzumab. 
 
CD24 
C
D
44
 
Figure 9. Detection of BCSCs through the evaluation of the expression of CD44 and CD24 by flow 
cytometry in MAMBO89 (A), Mi6 (B) and MAMBO38 (C) cell lines. 
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The efficacy of anti-angiogenic therapies was later analyzed in vitro, studying the 
inhibition of tumor cell lines proliferation or the effect on the ability of forming tubes 
on Matrigel. 
 
2.1 In vivo sensitivity to sunitinib and pazopanib 
Since FVBhuHER2 tumors and Δ16-HER2 ones show different patterns of angiogenesis 
that affect drug distribution and have different levels of expression of VEGFR2, the 
anti-angiogenic drugs sunitinib and pazopanib were tested in vivo to explore not only 
the effect on tumor growth but also the impact on tumor vascularization. 
To do that, two Mouse-Derived Isografts (MDI) were created. Fragments of five 
autochthonous mammary carcinomas from FVBhuHER2 mice were subcutaneously 
injected in 15 FVB non-transgenic mice. The same was done with the fragments of nine 
tumors of Δ16-HER2 mice. 
Tumor growth was monitored weekly for all the duration of the experiment. 
When tumors grew and became palpable, mice were divided into three groups to 
receive sunitinib 60 mg/kg, pazopanib 100 mg/kg or the vehicle in which the drugs 
were dissolved (sterile methocel 0.5% + tween80 0.4% in tap water). Drugs were 
administered orally for four weeks, five days a week. 
One mouse of each pazopanib group and one mouse of FVBhuHER2 MDI control 
group were excluded from the analysis, due to premature death of the animals. 
All the other mice were euthanized the week after the end of the treatment. 
Necropsy was performed, and the tumors were collected for histological and molecular 
analysis. 
FVBhuHER2 MDI tumors showed a sensitivity to sunitinib starting from the 
second week of treatment. At the end of the experiment, tumor growth had an 
inhibition of 70.3%. No effect was observed upon treatment with pazopanib (figure 
10A). 
On the other hand, sunitinib was effective on Δ16-HER2 MDI tumors starting 
from the second week of treatment as well, reaching a tumor growth inhibition of 
88.4% at the end of the experiment. Moreover, no tumor growth was observed until the 
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end of the treatment. Pazopanib was also effective starting from the third week of 
treatment, with a final tumor growth inhibition of 48.4% (figure 10B). 
As a conclusion, sunitinib resulted effective either on FVBhuHER2 MDI tumors 
or Δ16-HER2 ones, but the effect was bigger on the latter. Pazopanib was effective only 
on Δ16-HER2 tumors, but the tumor growth inhibition was lower and occurred later 
than sunitinib. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. In vivo sensitivity to anti-angiogenic drugs on tumors induced by the subcutaneous injection of 
fragments of FVBhuHER2 (A) and FVBΔ16 (B) autochthonous mammary carcinomas, as kinetics of tumor 
growth from beginning of therapy. Vehicle: black line. Sunitinib: orange line. Pazopanib: light blue line. 
Each point represents the mean and the SEM of the volumes of 4-5 tumors. Statistical analysis (Student’s t 
test): *=p<0.05; **=p<0.01; ***=p<0.001. 
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2.1.1 Histology of treated tumors 
Tumors of treated mice were compared to untreated ones from the histological point of 
view. Immunohistochemistry was performed using an antibody against CD31 to detect 
and quantify the vessels (figure 11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Immunohistochemistry of treated and untreated FVBhuHER2 (A, C and E) or Δ16-HER2 (B, D 
and F) MDI tumors. A and B: vehicle. C and D: sunitinib. E and F: pazopanib. An anti-CD31 antibody was 
used to stain in red endothelial cells. Pictures A, C and E were taken with a 5x magnification; pictures B, 
D and F were taken with a 10x magnification. 
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No effect on vascularization was observed on FVBhuHER2 MDI tumors upon 
treatment (figure 12A). The only effect that was noticeable in these tumors was the 
significant increase of tumor necrosis in sunitinib-treated samples (figure 12B). This 
effect could explain the sensitivity of these tumors to this drug. 
On the contrary, the treatment with sunitinib and pazopanib had a direct effect 
on vascularization of Δ16-HER2 MDI tumors, significantly reducing the vascular 
density, that is the number of vessel per tumor area. In particular, vascular density was 
reduced by the 47.6% by sunitinib, and by the 50.4% by pazopanib (figure 12C). 
Therefore, sunitinib and pazopanib were effective both as anti-tumoral and anti-
angiogenic agents in Δ16-HER2 MDI tumors, whereas in FVBhuHER2 MDI tumors 
only sunitinib had an anti-tumoral effect likely by necrosis induction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Effect on vascularization of sunitinib (white bars) and pazopanib (grey bars) in FVBhuHER2 (A 
and B) or Δ16-HER2 (C) tumors, compared to vehicle group (black bars). A and C: quantification of 
vessels as number of CD31+ pixels per tumoral area. B: percentage of necrotic cells inside the tumors. Each 
bar represents the mean and the SEM of the analysis of 4-5 tumors. Statistical analysis (Student’s t test): 
*=p<0.05; **=p<0.01; ***=p<0.001. 
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2.1.2 Molecular analysis of treated tumors 
The MDI tumors treated with sunitinib or pazopanib were also analyzed from the 
molecular point of view, in order to detect any variation in the expression of 
angiogenesis-related markers induced by the treatment with the two anti-angiogenic 
drugs. The expression of VEGF-A, VEGFR2, COX-2, CD31 and CD146 was evaluated 
by Real Time qPCR (figure 13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In FVBhuHER2 MDI tumors, the expression of VEGFR2 and PECAM1 was lower 
in sunitinib-treated tumors. No other significant difference in expression was observed 
(figure 13A). 
Figure 13. Expression of angiogenesis-related genes by Real Time qPCR in FVBhuHER2 (A) or Δ16-HER2 
(B) tumors treated with vehicle (black bars), sunitinib (orange bars) or pazopanib (light blue bars). Each 
bar represents the mean and the SEM of ΔCt for each tumor (n=4-5). Housekeeping gene: mTBP. 
Statistical analysis (Student’s t test): *=p<0.05; **=p<0.01.  
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On the other hand, VEGF-A expression was lower in treated Δ16-HER2 MDI 
tumors compared to control ones. Even if statistical significance was not reached, some 
other tendencies were observed: the slightly higher expression of VEGFR2 in 
pazopanib-treated samples, and the expression of CD31 that is slightly lower in 
sunitinib-treated tumors and a little bit higher in pazopanib-treated ones (figure 13B). 
 
2.2 Combined therapy in vivo: sunitinib plus trastuzumab 
As previously shown, sunitinib was less effective on HER2-expressing tumors than 
Δ16-expressing ones. Moreover, HER2-expressing cells or tumors are less responsive to 
trastuzumab (Palladini et al., 2017), either in preventive or therapeutic setting. 
Therefore, a combined therapy approach including sunitinib and trastuzumab was 
tested to try to obtain a better pharmacological response in FVBhuHER2 model, since it 
was less sensitive to anti-angiogenic and anti-HER2 drugs than Δ16-HER2 model. 
To do so, twenty-five tumor-free FVBhuHER2 female mice were subcutaneously 
injected with fragments from six autochthonous mammary carcinomas of FVBhuHER2 
mice to create a MDI model. Tumor growth was monitored weekly, and when the 
tumors became palpable, the animals were divided into five experimental groups: 
vehicle of sunitinib, sunitinib, trastuzumab, sunitinib and then trastuzumab, 
trastuzumab and then sunitinib. 
Sunitinib was administered at a dose of 60 mg/kg in methocel 0.5% + tween80 
0.4% in tap water for four weeks, five times a week. Trastuzumab was administered 
intraperitoneally at a dose of 4 mg/kg in saline, twice a week for four weeks. In the 
combined setting, the two drugs were administered in sequence to evaluate whether 
the order of administration of the drugs were important for the therapeutic result. 
Therefore, four weeks of treatment with a drug were followed by four weeks of 
treatment with the other drug. 
Tumor dimensions were measured weekly throughout the experiment to 
monitor the tumor growth inhibition (figure 14). 
In the monotherapy setting, both drugs were effective in slowing down tumor 
growth (figure 14A). Sunitinib reduced tumor volume by 85.7% at the end of the 
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experiment, whereas trastuzumab had an effect by 58.8% compared to control. 
Therefore, sunitinib was more effective than trastuzumab. 
In the combined therapy setting (figure 14B), the first segment of both treatment 
lines (that is before the switch of therapy) reflected the slope of their respective line in 
monotherapy setting. After the change of treatment, the slope of both lines changed 
and at the end of the follow-up the last points of each line were almost superimposed. 
 
 
   
 
Figure 14. In vivo therapy with sunitinib and/or trastuzumab on tumors induced by the subcutaneous 
injection of fragments of FVBhuHER2 autochthonous mammary carcinomas, as kinetics of tumor growth 
from beginning of therapy. Each point represents the mean and the SEM of the volumes of 5 tumors. A: 
therapy with sunitinib (orange line) or trastuzumab (blue line), compared to control group (vehicle, black 
line). B: combined therapy as sunitinib followed by trastuzumab (pink line) or trastuzumab followed by 
sunitinib (green line). Statistical analysis (Student’s t test): *=p<0.05; **=p<0.01. 
A 
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Because of a great variability among the two groups, the SEM were so big that 
the difference with the control group was not statistically significant. Anyway, at the 
end of the experiment there was no difference in terms of benefit in tumor growth rate 
according to the order of administration of the two drugs.  
 
2.3 In vitro sensitivity to sunitinib and pazopanib 
The impact on proliferation of anti-angiogenic drugs such as sunitinib and pazopanib 
has been assessed in vitro using cell lines with different levels of expression of the two 
isoforms of HER2, to evaluate the intrinsic sensitivity of these cell lines to the drugs. 
The cell lines that were considered were MAMBO89 (derived from a 
FVBhuHER2 tumor) and Mi6 (derived from a Δ16-HER2 tumor). Cells were seeded in 
adherent conditions and drug sensitivity was evaluated after 24, 48 and 72 hours after 
treatment by cell count. 
MAMBO89, which expresses full-length HER2, resulted sensitive only to 
pazopanib at 72 hours after treatment, with a growth inhibition of 64.6% (figure 15A 
and 15C). 
The Δ16-expressing cell line Mi6 showed sensitivity to both drugs. Sunitinib was 
already effective in inhibiting cell proliferation after 24 hours of treatment, reaching a 
growth inhibition of 45.5% after 72 hours. Pazopanib was effective too, but only after 
48 and 72 hours of treatment, with a growth inhibition of 18% and 49.9% respectively 
(figure 15B and 15D). 
In conclusion, both drugs were effective in inhibiting cell growth in vitro, with 
some differences. First of all, in Mi6 cell line the effectiveness was evident earlier than 
in MAMBO89 cells. Moreover, MAMBO89 showed resistance to sunitinib but not to 
pazopanib, even if the effect of pazopanib was observable only after 72 hours. 
 
Results 
98 
 
 
 
 
 
 
2.3.1 Influence of anti-angiogenic drugs on tube formation 
Since that FVBhuHER2 cell lines MAMBO89 and MAMBO43 showed a modest 
capability of forming lacunae on Matrigel, whereas this attitude was absent in the Δ16-
HER2 cell line Mi6, the effect of anti-angiogenic drugs on this ability has been 
explored. 
MAMBO89 and Mi6 cells were seeded on a 6-well plate. The medium was 
replaced with drug-containing fresh media the day after. 24 hours after treatment, cells 
were harvested and seeded on Matrigel, according to the protocol of the Tube 
Formation Assay. After 18 hours, the lacunae formed have been counted, dividing them 
by dimension as described before.  
Figure 15. In vitro sensitivity to anti-angiogenic drugs of MAMBO89 (A, C) and Mi6 (B, D) cell lines. A 
and B: total number of cells per well at 24, 48 and 72 hours after treatment with sunitinib 5 μM (orange 
line) or pazopanib 5 μM (light blue line), compared to untreated cells (black line) and DMSO-treated cells 
(grey line). Each point represents the mean and the SEM of two replicates. C and D: percentage of 
growth over control (untreated cells). Each bar represents the mean and the SEM of the ratio between the 
total number of treated cells and the mean total number of control cells. DMSO 0.05%: grey bars. 
Sunitinib: orange bars. Pazopanib: light blue bars. Statistical analysis (Student’s t test): *=p<0.05; 
**=p<0.01; ***=p<0.001. 
D C 
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Mi6 was unable to form any tube in any condition. On the contrary, the treatment 
with sunitinib reduced the number of tubes compared to the untreated control by 
almost 4 times in MAMBO89 cell line (table 2). 
 
 
 
 
 
 
 
 
 
Therefore, sunitinib, which was not able to arrest cell growth in adherent cells, 
was effective in reducing the formation of vessel-like structures on Matrigel of 
MAMBO89 cell line.  
 
 
3. Angiogenesis and sensitivity to anti-angiogenic 
drugs in triple-negative breast cancer 
The Tube Formation Assay showed that MAMBO38 and MDA-MB-231, the two HER2-
negative cell lines that were used, had a great attitude of forming tubes in vitro. The test 
performed on MAMBO89 cells revealed that sunitinib is able to reduce this ability, that 
is linked to vasculogenic mimicry (Maniotis et al., 1999). 
MDA-MB-231 are known to do mimic endothelial cells in vivo, reflecting the 
ability shown on Matrigel (Plantamura et al., 2014). Therefore, MDA-MB-231 were 
injected in immunodeficient mice and treated with sunitinib in order to test the 
Treatment 
Small 
tubes 
Medium 
tubes 
Big 
tubes 
Total Average 
Untreated 
32 4 0 36 
27 
15 3 0 18 
DMSO 0.05% 
63 14 4 81 
75 
61 6 1 68 
Sunitinib 5 μM 
8 0 0 8 
8 
7 0 0 7 
Pazopanib 5 μM 
28 0 1 29 
25 
20 0 0 20 
Table 2. Number of vessel-like structures (tube) in MAMBO89 cell line by Tube Formation Assay in vitro 
after treatment with sunitinib 5 μM or pazopanib 5 μM. Small tubes = diameter smaller than 0.5 mm; 
medium tubes = diameter of between 0.5 and 1.5 mm; big tubes = diameter bigger than 1.5 mm. 
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sensitivity to this drug in terms of tumor growth. The sensitivity has been also 
evaluated in vitro. 
The sensitivity to anti-angiogenic drugs was also studied on MAMBO38 cell line, 
both on adherent conditions and in 3D-culture. 
 
3.1 In vivo sensitivity to sunitinib in triple-negative breast cancer 
To test the efficacy of sunitinib in vivo on human HER2-negative breast cancer, MDA-
MB-231 cells were injected orthotopically in both flanks of twelve 8-week-old female 
NOD-SCID mice. The experiment was performed at the Vascular Morphogenesis Lab 
directed by Dr. Cláudio A. Franco (Instituto de Medicina Molecular, Faculdade de 
Medicina da Universidade de Lisboa, Lisbon, Portugal). 
All the tumors were palpable two weeks after the injection, and six animals were 
treated with sunitinib 60 mg/kg for twenty consecutive days. The other six mice 
received the vehicle in which sunitinib was dissolved (sterile methocel 0.5% in tap 
water). The mice were euthanized to collect the tumors for further analyses one week 
after the end of the therapy. Due to excessive tumor growth, three mice of the control 
group had to be euthanized a few days earlier than the other animals. 
Tumor growth was monitored throughout the experiment to evaluate the 
potential inhibition of proliferation after the treatment. 
The effect of sunitinib on tumor growth was statistically evident starting from the 
fourth week after cell injection, that was after two weeks of treatment. The drug was 
able to reduce the tumor volume by the 43.4% compared to the control group, at the 
end of the experiment (figure 16). 
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3.2 In vitro sensitivity to sunitinib and pazopanib in HER2-negative cell lines 
The impact on proliferation of anti-angiogenic drugs such as sunitinib and pazopanib 
has been evaluated in vitro using cell lines with different levels of expression of the two 
isoforms of HER2. 
The cell lines that were considered were the human triple-negative breast cancer 
cell line MDA-MB-231, and MAMBO38, which was derived from the tumor induced by 
the injection of a cell line derived from a FVBhuHER2 tumor and which underwent a 
EMT and lost HER2 expression. 
The sensitivity to sunitinib and pazopanib was first tested on MDA-MB-231 cells, 
evaluating the cell proliferation at 24, 48 and 72 hours after treatment by cell count 
(figure 17).  
The human triple-negative cell line MDA-MB-231 was sensitive to both drugs 
after 72 hours of treatment. Sunitinib caused a 40.9% inhibition of cell growth, whereas 
pazopanib was able to reduce cell proliferation only by 28.3%.  
Figure 16. In vivo sensitivity to sunitinib on tumors induced by the subcutaneous injection of MDA-MB-
231 cells, as kinetics of tumor growth after cell injection. Vehicle: black line. Sunitinib: orange line. Each 
point represents the mean and the SEM of the volumes of 6-12 tumors (two tumors per mouse). Statistical 
analysis (Student’s t test): *=p<0.05; **=p<0.01. 
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The sensitivity to sunitinib and pazopanib has been tested in a slightly different 
way in the cell line MAMBO38. Cell proliferation was evaluated at 24 and 72 hours 
after treatment through the adding of WST-1 reagent, a compound that is cleaved by 
mitochondrial dehydrogenases of viable cells into a compound that can be quantified 
by absorbance measurement.  
Sunitinib was effective both at 24 and 72 hours after treatment, with a growth 
inhibition of 51.3% and 49.3%. Pazopanib was effective only at 72 hours after 
treatment, inhibiting cell proliferation by 54.7% (figure 18). 
 
 
 
A B 
Figure 18. In vitro sensitivity to anti-angiogenic drugs of MAMBO38 cell line. A: OD measurement at 24 and 
72 hours after treatment with sunitinib 5 μM (orange line) or pazopanib 5 μM (light blue line), compared to 
untreated cells (black line) and treatment with DMSO 0.1% (grey line). Absorbance was measured one hour 
after the adding of WST-1 reagent. Each point represents the mean and the SEM of three replicates. B: 
Percentage of growth over control (untreated cells). Each bar represents the mean and the SEM of the ratio 
between the mean absorbance of treated cells and of control cells. DMSO 0.1%: grey bars. Sunitinib: orange 
bars. Pazopanib: light blue bars. Statistical analysis (Student’s t test): **=p<0.01; ***=p<0.001. 
A B 
Figure 17. In vitro sensitivity to anti-angiogenic drugs of MDA-MB-231 cell lines. A: total number of cells 
per well at 24, 48 and 72 hours after treatment with sunitinib 5 μM (orange line) or pazopanib 5 μM 
(light blue line), compared to untreated cells (black line) and DMSO-treated cells (grey line). Each point 
represents the mean and the SEM of two replicates. B: Percentage of growth over control (untreated 
cells). Each bar represents the mean and the SEM of the ratio between the total number of treated cells 
and the mean total number of control cells. DMSO 0.05%: grey bars. Sunitinib: orange bars. Pazopanib: 
light blue bars. Statistical analysis (Student’s t test): *=p<0.05; **=p<0.01. 
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The influence of anti-angiogenic therapies on MAMBO38 cell line has been also 
explored in 3D-culture. Cells were seeded in soft agar in a 24-well plate, in presence or 
not of sunitinib 5 μM or pazopanib 5 μM. After two weeks, colonies were counted 
under an inverted microscope, arbitrary defined as every cell aggregate bigger than 1 
mm.  
Both drugs were extremely effective (table 3): no colonies were present at all after 
14 days of treatment, whereas 30-40 colonies had formed in control wells (p<0.001 by 
the Student’s t test). 
Therefore, MAMBO38 cells were dramatically sensitive to both drugs both in 3D-
culture and adherent conditions. 
Treatment Count replicates Average 
Untreated 29 26 35 25 23 35 40 30 
DMSO 0.05% 41 42 44 39 32 41 34 39 
Sunitinib 5 μM 0 0 0 0 0 0 0 0 
Pazopanib 5 μM 0 0 0 0 0 0 0 0 
 
 
In conclusion, both sunitinib and pazopanib were effective on HER2-negative cell 
lines in vitro and in vivo. The effectiveness of sunitinib was evident earlier than the 
effect of pazopanib in both MDA-MB-231 and MAMBO38 cells in vitro in adherent 
conditions. Both drugs had an impressive effect on MAMBO38 cell line in 3D-culture. 
Table 3. Number of colonies of MAMBO38 cell line by seeding in 3D-culture after treatment with sunitinib 
5 μM or pazopanib 5 μM. Aggregates bigger than 1 mm were considered as colonies. Colonies were 
counted by two different researchers at 7 different times 14 days after seeding. 
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Preclinical models developing human HER2-positive mammary carcinoma have been 
created to study mammary carcinogenesis. Three mouse models, transgenic for full-
length HER2 and/or its splice variant Δ16, have been used in this thesis. The tumors of 
these three models showed different macroscopic appearance and pattern of 
vascularization. FVBhuHER2 tumors, that are usually hemorrhagic and have a soft 
texture, displayed few large vessels. Concordant association between high HER2 
expression and atypical vessels was found in human breast cancer: dilated capillaries 
(called “cavitary” structures) were associated with lymphovascular invasion and 
higher grade in HER2-positive breast carcinoma (Senchucova et al., 2015). On the other 
hand, Δ16-HER2 tumors, that usually have a solid and whitish aspect, showed 
numerous vessels with a smaller diameter. F1 tumors, which derive from a double-
transgenic mouse model, could show both characteristics (Palladini et al., 2017). 
To better understand the role of HER2 and its splice isoform Δ16 in tuning 
different vascular phenotypes, vascular architecture of F1 tumors has been analyzed 
considering that one isoform or both can be expressed. Interestingly, regardless of the 
level of expression of Δ16, immunostaining of vessels revealed that the F1 tumors 
which highly express full-length HER2 display the same phenotype of FVBhuHER2 
tumors. Only the vascular pattern of F1 tumors with low levels of HER2 and high 
levels of Δ16 resembles the one of Δ16-HER2 tumors. This evidence is the first proof 
that full-length HER2 has a dominant and crucial role in influencing the 
vascularization of the tumor. 
The second evidence was obtained through the study of the vascularization in a 
model of modulation of the expression of HER2. This model is made of two MDIs 
created through serial transplants of F1 tumors, in which the levels of HER2 decrease 
or increase while the expression of Δ16 remains high and stable over consecutive 
passages. Analyzing the vessel density and the mean vascular area of the tumors of 
different passages, it was clear that a change in expression level of HER2 was always 
associated with a change in the vascular phenotype. In particular, a gain in HER2 
expression conferred the vascular phenotype with few large vessels, but when HER2 
expression got lost, the vascular pattern consisted of many small vessels like Δ16-HER2 
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tumors. In this sense, it is more evident that the presence of a high expression of full-
length HER2 strongly influences tumor angiogenesis in a dynamic way. 
The different vascularization may impact on functionality of the vascular 
network of the tumors. In fact, distribution and permeability seemed to be affected, 
depending on the vascular phenotype. The presence of a smaller number of larger 
vessels seemed to allow a poorer distribution of drugs, as it has been proved through 
the analysis of the accumulation of doxorubicin and trastuzumab inside the tumors. A 
lower permeability may explain why HER2-expressing tumors are less sensitive to 
targeted drugs in vivo (Castagnoli et al., 2014; Palladini et al., 2017). In fact, the 
reduction of vessel diameter has been associated with higher permeability (Chauhan et 
al., 2012). 
If the vascularization driven by the two isoforms is so different, then HER2 and 
Δ16 must trigger different pathways. This means that the differences between the two 
angiogenic patters must also involve different molecular partners. In fact, Δ16-
expressing tumors were enriched in VEGF-A and VEGFR2 expression. Several other 
genes that were differently expressed in FVBhuHER2 and Δ16-HER2 may explain the 
different phenotypes. For instance, Angiopoietin-1 and TIMP-1 were more expressed in 
tumors of FVBhuHER2 mice. On the other hand, EGF was more expressed in Δ16-
HER2 tumors. Since this growth factor can increase VEGF-A and VEGFR2 expression 
(van Cruijsen et al., 2005), it could explain what was previously found.  
These findings may suggest that the vascular network is less mature in 
FVBhuHER2 tumors. In fact, numerous angiogenic factors involving sprouting 
angiogenesis were more expressed in these tumors, and that may imply that the 
angiogenesis process occurs in a more active manner in these tumors rather than in 
Δ16-HER2 ones. For example, Angiopoietin-1 and TIMP-1, which were more expressed 
in FVBhuHER2 tumors, are responsible of the recruitment of endothelial progenitors 
and of the proliferation of mature endothelial cells respectively (Carmeliet and Jain, 
2000; Baker et al., 2002). Metalloproteinases, such as MMP-9 and MMP-3, were also 
more expressed in FVBhuHER2 tumors. This means that extracellular matrix is more 
degraded to let the sprouts invade the tissues. Moreover, factors that stimulate 
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migration and endothelial precursors recruitment were more expressed, such as 
osteopontin, PAI-1, PlGF-2 and PDGF-AB/BB. Likely, the maturation and remodeling 
of vessels are somehow inhibited or less activated, leading to a less coordinated 
process and a less regular vascularization in FVBhuHER2 tumors.  
On the other hand, Δ16-HER2 vascularization might be more regular but more 
developed, in terms of number of branches. Higher permeability and number of 
vessels can explain a better and more efficient distribution of drugs. Moreover, 
Angiopoietin-1, which was more expressed in FVBhuHER2 tumors, reduces the 
permeability of blood vessels: this can also explain why the drugs accumulate less than 
in Δ16-HER2 tumors.  
Another hint about the less regular vascularization in FVBhuHER2 tumors has 
been given by the Tube Formation Assay, using cell lines derived from FVBhuHER2 
and Δ16-HER2 tumors. This technique allows to understand whether tumor cells have 
the tendency to show vasculogenic mimicry (VM; Maniotis et al., 1999). It emerged that 
the FVBhuHER2 cell line MAMBO89 was somehow able of forming vessel-like 
structures, whereas the Δ16-HER2 cell line Mi6 was not. 
There can be many possible explanations to that. First, it is known in literature 
that VM and stemness have a strong link. CD44+ CD24-/low Lin- cells were defined as 
Breast Cancer Stem Cells (BCSCs) and showed stem-like features (Al-Hajj et al., 2003). 
MDA-MB-231 cells are known to produce a large number of lacunae on Matrigel, and 
are strongly enriched with CD44+ CD24-/low cells (An et al., 2015). Interestingly, the 
HER2-negative cell line MAMBO38 showed the same behavior, and the population of 
CD44+ CD24-/low cells was as present as in MDA-MB-231 cell line. In fact, this 
population is higher than 96% in both cell lines. In Mi6 cells the CD44+ CD24-/low cells 
were absent, whereas in MAMBO89 cell line they reach the 18% of the total population. 
This matches with the limited but present capability of MAMBO89 cells to form vessel-
like channels in vitro. 
However, different stem-like populations have been identified in human breast 
cancer and in mouse models of mammary carcinogenesis. For instance, Castagnoli and 
colleagues found that a stem cell population, defined as CD29high/CD24+/Sca-1low, is 
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present in Mi6 cell line. This population conferred greater tumor engraftment in serial 
dilutions compared to MAMBO89 (Castagnoli et al., 2017). Mi6 has stem-like features 
but they are not directly linked to BCSCs, defined as CD44+ CD24-/low Lin-. It is possible 
that the stem population found by Castagnoli and his group is mainly linked to 
tumorigenesis, whereas CD44+ CD24-/low Lin- cells can also have an implication in 
angiogenesis and VM. 
VM has also been linked to the expression of COX-2 (Kirschmann et al., 2012). As 
demonstrated, the expression of Δ16 confers a lower expression of its transcript and 
this might explain the absent capability to form vascular networks in vitro. COX-2 has 
also been linked to CD44+ CD24-/low Lin- cells: the production of prostaglandins sustains 
the proliferation of this population (Pang et al., 2016). This also supports the hypothesis 
that HER2-driven angiogenesis is less regular in comparison with Δ16-driven one, and 
that VM might be present in HER2-expressing tumors. 
The capability of forming vessel-like structures was affected after treatment with 
sunitinib in MAMBO89 cell line. Sunitinib has been found to reduce CSCs in many 
tumor types, such as renal, breast (Brossa et al., 2015; Czarnecka et al., 2016) and 
prostate cancer (Diaz et al., 2015). It is possible that the reduced ability of forming tubes 
showed by MAMBO89 on Matrigel is due to this specific action of sunitinib. 
Therefore, the irregular angiogenesis of HER2-expressing tumors might involve 
VM and other structures such as vascular lacunae, which are sustained by a higher 
presence of a CD44+ CD24-/low population and a greater expression of COX-2. 
The sensitivity to sunitinib and pazopanib was studied in triple-negative breast 
cancer. Two cell lines were used: the human MDA-MB-231 and the murine MAMBO38. 
In both cell lines the CD44+ CD24- population is present at a very high percentage.  
First of all, MDA-MB-231 cells were injected in NOD-SCID mice to test the 
effectiveness of sunitinib. Tumor volume was significantly reduced at the end of the 
experiment, thus indicating a sensitivity to this drug that has been confirmed in vitro. 
Since MDA-MB-231 are known to form VM channels both in vitro and in vivo 
(Plantamura et al., 2014), sunitinib might have had a dual effect: on one hand, it could 
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have affected the formation of vessels and of VM vessel-like tubes; on the other hand, it 
could have had a direct impact on cell proliferation. 
The sensitivity to sunitinib and pazopanib was also tested in vitro on MAMBO38 
cells. In adherent conditions, both drugs were effective after 72 hours of treatment, but 
a small effect in sunitinib-treated cells was evident just after 24 hours. Later, the 
sensitivity to sunitinib and pazopanib was tested in 3D-culture, to better analyze the 
effect of the drugs in a condition that better resembles the in vivo situation. The effect of 
the drugs was dramatic, since no colonies had grown after 14 days of treatment, 
compared to the control wells in which 30-40 colonies were present. This proves that 
sunitinib has an anti-proliferative effect on triple-negative breast cancer. 
The sensitivity to sunitinib and to pazopanib in relation to HER2 and Δ16 has 
been evaluated both in vitro and in vivo. In vivo, Δ16-HER2 tumors were sensitive to 
both drugs. Differently from FVBhuHER2 tumors, vascularization was affected, in 
terms of reduction of vessel density. This effect of sunitinib and pazopanib has been 
reported in renal cell carcinoma (Vasudev et al., 2013) and in breast cancer (Young et al., 
2010). The drugs had not only an anti-tumoral effect, therefore causing the decrease of 
tumor growth, but also showed an anti-angiogenic action through the significant 
reduction of vessel density. 
There can be several possible explanations to this different sensitivity between 
the two types of tumors. For example, Δ16-HER2 tumors express more VEGFR2 than 
FVBhuHER2, that is one of the targets of the drugs. The more the target is present, the 
more the effect is evident. Moreover, the higher perfusion of Δ16-HER2 drugs may 
distribute the drugs in a more efficient way, leading to an increased effect.  
Interestingly, the anti-tumoral effect of sunitinib was higher than the effect of 
pazopanib in Δ16-HER2 tumors. This can be explained taking into account that 
sunitinib can block a higher number of targets than pazopanib. In fact, sunitinib 
inhibits VEGFRs, PDGFRs, c-Kit, RET, CSF1R and Flt-3, whereas pazopanib inhibits 
only VEGFR2, PDGFRs and c-Kit. 
For instance, RET is a tyrosine kinase receptor that is involved in many cancer 
types. Gain-of-function somatic mutations have been identified in papillary thyroid 
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carcinoma, lung adenocarcinoma and chronic myelomonocytic leukemia. Wild-type 
RET has a role also in other tumor types, such as mammary carcinoma, pancreatic 
cancer, acute myeloid leukemia and colon carcinoma, increasing aggressiveness, 
invasivity, tumor cell proliferation and drug resistance (Mulligan, 2014). The 
expression of RET has not been evaluated in this thesis, but it is possible that its 
presence has a role in increasing the sensitivity of Δ16-HER2 tumors to sunitinib. 
In Δ16-HER2 tumors, no effect in tumor necrosis has been found. On the 
contrary, sunitinib increased tumor necrosis in FVBhuHER2 tumors. In fact, the 
percentage of necrotic cells in pazopanib-treated tumors was the same as in the tumors 
of the control group, and no effect on tumor growth was observed after the treatment 
with this drug. This could explain the sensitivity to this drug, especially in the light of 
the fact that sunitinib is known to induce tumor necrosis (Verhoest et al., 2014). 
The treatment with the two anti-angiogenic drugs have led to modifications of 
the level of expression of angiogenic-related proteins. The most relevant alteration that 
has been found is the significant decrease in VEGF-A expression in treated Δ16-HER2 
MDI tumors compared to control ones. This might be due to the block of angiogenesis 
and the reduction of tumor dimensions. 
Since a lesser effect was observed in FVBhuHER2 MDI tumors in terms of 
sensitivity to sunitinib, a combined therapy approach involving sunitinib and 
trastuzumab was tested to try to obtain a better outcome on these tumors. 
The tumor necrosis observed upon treatment with sunitinib likely recruited 
immune cells, which may mediate the immunological mechanisms of effectiveness of 
trastuzumab, such as ADCC. A higher presence of immune cells might induce a higher 
trastuzumab-mediated anti-tumoral response. Since there is no normalization of the 
vasculature according to the Jain’s concept, it was logical to hypothesize that the only 
opportunity to get a better effect in placing sunitinib before trastuzumab would have 
been due to the recruitment of immune cells after tumor necrosis induction. For this 
reason, trastuzumab was administered after sunitinib and not at the same time. This 
approach was compared with the control group, the groups treated in monotherapy 
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with sunitinib or trastuzumab and the group that received trastuzumab followed by 
sunitinib. 
In the monotherapy setting, both drugs were effective in reducing tumor growth 
but the effect of sunitinib was greater. Trastuzumab, in fact, was less effective on 
HER2-expressing cell line MAMBO89 compared to the Δ16-expressing cell line Mi6, 
both in vitro and in vivo (Castagnoli et al., 2014; Palladini et al., 2017), thus indicating an 
intrinsic less sensitivity of the full-length isoform. 
In the combined therapy setting, no difference was found regardless the order of 
drug administration. Therefore, unlike the initial hypothesis, there is no advantage in 
administering sunitinib and then trastuzumab, or the other way around. 
To better analyze the sensitivity to sunitinib and pazopanib, the effect of the two 
drugs has been evaluated on cell proliferation in vitro, according to the expression of 
full-length HER2 and Δ16. MAMBO89 cell line showed no sensitivity to sunitinib and 
some sensitivity to pazopanib in vitro. The opposite observation between the 
treatments in vitro and in vivo can be explained with the effect on tumors: sunitinib 
caused an increase of tumor necrosis, that limited tumor growth and likely recruited 
immune cells that contributed to the decline of tumor cell proliferation. Pazopanib was 
slightly able to slow down cell proliferation in vitro, but no effect was detected in vivo, 
probably because of the lack of induction of tumor necrosis. Moreover, the approach in 
vitro in adherent conditions is less close to the in vivo situation: this can also explain the 
discrepancy between the different studies. 
Regarding Δ16, Mi6 cell line showed sensitivity to both sunitinib and pazopanib 
in vitro. The sensitivity to sunitinib was evident after only 24 hours, whereas the effect 
of pazopanib was observable later. These data confirmed the results of the treatment in 
vivo, showing sensitivity to both drugs. This probably means that the anti-tumoral 
effect of sunitinib and pazopanib is due to the inhibition of cell proliferation. 
In conclusion, for the first time the angiogenesis sustained by full-length HER2 
and its splice variant Δ16 has been extensively explored, revealing differences from the 
phenotypic, functional, molecular and therapeutic point of view. In particular, the 
vascularization with few large vessels typical of HER2-expressing tumors is less 
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permeable to drugs and less sensitive to anti-angiogenic drugs such as sunitinib and 
pazopanib than Δ16-HER2 tumors, where a vascular pattern with numerous small 
vessels and a higher expression of VEGF-A and VEGFR2 are present. HER2 seemed to 
have a dominant role in determining these molecular and phenotypic aspect of 
vascularization in tumors. A less regular angiogenesis, likely with VM channels, may 
explain these characteristics in FVBhuHER2 tumors, which is affected by sunitinib in 
vitro through the decrease of VM activity. CD44+ CD24-/low cells might have a role in 
HER2-driven angiogenesis, likely inducing abnormal structures. Sunitinib was also 
effective on triple-negative breast cancer, both in vitro and in vivo. 
These findings suggest the importance of better study angiogenesis in cancer, in 
order to find new potential targets and improve pharmacological response. Moreover, 
additional analyses can be done to further study the impact of the two isoforms on 
vascularization and the differently expressed genes such as Angiopoietin-1, in order to 
better understand the relation between cancer, angiogenesis and drug response.  
The implication of HER2- or Δ16-driven angiogenesis can be studied in other 
therapeutic contexts, such as innovative immunological approaches. For instance, the 
relationship between vascularization and leukocytes distribution could be investigated 
in relation to the response of a novel anti-HER2 vaccine based on virus-like particles 
(VLP), which very recently showed a great effectiveness in FVBhuHER2 and Δ16-HER2 
models both in prophylactic and therapeutic settings (Palladini et al., 2017). 
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